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Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults at
the time of the ﬁrst psychotic episode of delusions and hallucinations. These positive symptoms
can be controlled in most patients by currently-available antipsychotics. Conversely, they
are poorly effective against concomitant neurocognitive dysfunction, deﬁcits in social cognition
and negative symptoms (NS), which strongly contribute to poor functional outcome. The precise
notion of NS has evolved over the past century, with recent studies – underpinned by novel
rating methods – suggesting two major sub-domains: “decreased emotional expression”, incor-
porating blunted affect and poverty of speech, and “avolition”, which embraces amotivation,
asociality and “anhedonia” (inability to anticipate pleasure). Recent studies implicate a
dysfunction of frontocortico-temporal networks in the aetiology of NS, together with ao.2014.03.008
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M.J. Millan et al.646disruption of cortico-striatal circuits, though other structures are also involved, like the insular
and parietal cortices, amygdala and thalamus. At the cellular level, a disruption of GABAergic–
glutamatergic balance, dopaminergic signalling and, possibly, oxytocinergic and cannibinoider-
gic transmission may be involved. Several agents are currently under clinical investigation for
the potentially improved control of NS, including oxytocin itself, N-Methyl-D-Aspartate receptor
modulators and minocycline. Further, magnetic-electrical “stimulation” strategies to recruit
cortical circuits and “cognitive–behavioural–psychosocial” therapies likewise hold promise. To
acquire novel insights into the causes and treatment of NS, experimental study is crucial, and
opportunities are emerging for improved genetic, pharmacological and developmental model-
ling, together with more reﬁned readouts related to deﬁcits in reward, sociality and
“expression”. The present article comprises an integrative overview of the above issues as a
platform for this Special Issue of European Neuropsychopharmacology in which ﬁve clinical and
ﬁve preclinical articles treat individual themes in greater detail. This Volume provides, then, a
framework for progress in the understanding – and ultimately control – of the debilitating NS of
schizophrenia.
& 2014 Elsevier B.V. and ECNP. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1.1. Schizophrenia: core characteristics and
inadequate current management
Schizophrenia is a chronic, life-long and debilitating disorder
which is triggered in a complex, heterogeneous and multi-
factorial fashion by a diverse palette of genetic, epigenetic,
developmental and environmental risk factors (Figure 1)
(Millan, 2013; Sullivan et al., 2012; Rapoport et al., 2012).
It occurs with an incidence of at least 0.7% of the population
and, quite apart from personal distress, schizophrenia has a
huge socioeconomic burden, mostly in terms of indirect costs
like loss of employment and social support (Wittchen et al.,
2011). Diagnosis generally occurs in the young adult (or in late
adolescence) with the advent of the ﬁrst frank psychotic
episode, often in the wake of a high-risk, prodromal period in
which occasional and/or attenuated psychotic symptoms may
occur – though such high risk individuals may eventually transit
to another psychiatric disorder like depression (Fusar-Poli
et al., 2013a, 2014; Sabbag et al., 2011).
Psychosis corresponds to the most familiar cluster of cardinal
symptoms, termed positive, and including delusions and hallu-
cinations (Buchanan et al., 2010; Huxley and Fonseca, 2014;
Leucht et al., 2013; Tandon et al., 2013). Positive symptoms
have long been treated by “ﬁrst-generation” neuroleptics like
haloperidol and chlorpromazine; by clozapine; and by a range
of more recently-developed “second-generation” antipsycho-
tics including risperidone, olanzapine and aripiprazole (Asenjo-
Lobos et al., 2010; Citrome, 2013; Hartling et al., 2012; Leucht
et al., 2009, 2013; Naber and Lambert, 2009). Nonetheless,
control is often incomplete and some 20–30% of patients are
considered refractory (not responsive to at least two different
treatments). Despite decades of effort to ﬁnd successor agents
of improved efﬁcacy, clozapine remains the most effective
agent in otherwise non-responsive patients. However, as out-
lined below, clozapine shares the comparative inactivity of
other classes of antipsychotic for the management of neuro-
cognitive dysfunction, impaired social cognition and negative
symptoms (NS) (Asenjo-Lobos et al., 2010; Leucht et al., 2009,
2013).Deﬁcits in multiple domains of “neurocognition” are marked,
ranging from attention to working memory to executive
function, and they are little improved by medication, though
Cognitive Remediation Therapy (Section 4.7) is attracting
interest as an alternative therapeutic approach (Buchanan
et al., 2010; Carter and Barch, 2007; Kalkstein et al., 2010;
Leucht et al., 2009, 2013; Millan et al., 2012; Naber and
Lambert, 2009; Wykes et al., 2011). The poor response to
antipsychotics is hardly surprising since blockade of dopamine
D2 receptors, muscarinic M1 receptors, histamine H1 receptors
and α1-adrenoceptors will compromise mnemonic performance
and overwhelm any potentially beneﬁcial inﬂuence on cogni-
tion, such as that afforded by antagonism of frontocortical D3
receptors or α2-adrenoceptors (Brosda et al., 2014; Citrome,
2013; Millan et al., 2000, 2012; Nakajima et al., 2013). This
may at least partially explain why numerous mechanisms
evaluated as “add-on” therapies to antipsychotics have dis-
appointed for improving neurocognition (Buchanan et al.,
2011a, 2011b; Millan et al., 2012).
A further domain of poorly-treated impairment in schizo-
phrenia is social cognition which refers to mechanisms for
understanding and interpreting the mental states, gestures,
behaviours and facial expressions of others, and which also
embraces the understanding of verbal and non-verbal modes
of communication (Section 2.3) (Adolphs, 2009; Bora et al.,
2009; Brown et al., 2012; Brüne, 2005; Fitch et al., 2010;
Frith and Frith, 2012; Kalkstein et al., 2010; Millan and
Bales, 2013; Rushworth et al., 2013). By analogy to “neu-
rocognitive impairment”, deﬁcits in social cognition are
essentially refractory to existing antipsychotics yet, with
the exception of some preliminary trials with oxytocin
(Section 4.8), there have been comparatively few efforts
to speciﬁcally redress the compromised social cognition of
schizophrenia (Green et al., 2012; Meyer-Lindenberg et al.,
2011; Millan et al., 2012). This is unfortunate since impaired
social cognition has grave repercussions for functional out-
come and may drive other symptoms, including NS (Section
2.2) (Brüne, 2005; Foussias et al., 2014; Green et al., 2008,
2012; Hoe et al., 2012; Millan et al., 2012).
The NS of schizophrenia, which encompass blunted affect,
poverty of speech (alogia), amotivation, anticipatory anhedonia
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Figure 1 Negative symptoms throughout the lifespan of schizophrenia. Schizophrenia, which is triggered by a complex pattern
of genetic, epigenetic, developmental and environmental factors, is recognised at the moment of the ﬁrst well-deﬁned psychotic
episode (corresponding to positive symptoms). This usually occurs in late adolescence/young adulthood, but there are rare cases of
“early-onset” schizophrenia (13–18 years) and even childhood-onset schizophrenia (under the age of 13) (Masi et al., 2006; Rapado-
Castro et al., 2010). Once established, remission is rare (perhaps 10–15% of subjects recover after the ﬁrst episode), and the disease
follows a ﬂuctuating course punctuated by psychotic crises. Even when positive symptoms are well treated, NS resist control and
many patients display predominantly NS from the ﬁrst episode on. The term “deﬁcit syndrome” has been used for subjects who
manifest predominantly NS (perhaps up to a third in the chronic phase): however, it is not universally accepted and lack of psychosis
at ﬁrst admission suggests that the disorder would not be schizophrenia. In addition to transient and sub-diagnostic psychotic
symptoms in many (though not all) high-risk subjects, the prodromal phase is accompanied by prominent NS, as well as impaired
social cognition, neurocognitive and mood deﬁcits. Finally, NS like blunted affect predominate in childhood and early-onset
schizophrenia. Thus, NS are a poorly-treated and disabling feature throughout the lifespan of schizophrenia.
647Negative symptoms of schizophreniaand asociality, are likewise poorly-treated and severely inter-
fere with the functional status of patients (Table 1) (Blanchard
and Cohen, 2006; Boonstra et al., 2012; Kaiser et al., 2010;
Kirkpatrick et al., 2006; Kring and Elis, 2014; Konstantakopoulos
et al., 2011; Messinger et al., 2011). They comprise the subject
of this Special Issue of European Neuropsychopharmacology
which is, to the best of our knowledge, the ﬁrst of its kind – at
least in recent years – and embraces both clinical and
preclinical facets of NS.1.2. Organisation of the Special Volume, and aims
of this introductory article
Research and drug development in schizophrenia is at some-
thing of a watershed with the recognition that second-
generation antipsychotics do not offer any major advantages
in terms of efﬁcacy and breadth of therapeutic activity over
previously-available agents – and certainly not over clozapine
for refractory patients (Section 1.1).
This would seem, then, an opportune moment to devote a
Special Volume to incapacitating NS. As reﬂected in the 800
or so Hits generated by PubMed for “schizophrenia and NS”
in 2013, there has been a recent resurgence of interest
reﬂecting: improved insights into the interrelationship of NS
with other symptoms of schizophrenia; characterisation
of two inter-related but distinguishable sub-domains of
dysfunction, “decreased emotional expression” and “avoli-
tion”; the introduction of improved methods of clinicalevaluation; the imminent impact of Diagnostic and Statis-
tical Manual (DSM)-5; increasing awareness of “NS-like”
changes in other psychiatric and neurological disorders;
attempts to better couple NS to underlying neural patho-
physiology – if necessary transgressing nosological bound-
aries; ongoing pivotal trials of potentially novel medication;
and efforts to reﬁne and diversify the experimental study of
NS. Further, in the spate of disappointing results of mainly
add-on studies of new drugs for restoring neurocognition in
schizophrenia (Millan et al., 2012), there is an emerging
feeling that comparable efforts might better be invested in
novel pharmacotherapeutic and “alternative” strategies for
countering poorly treated NS – and interrelated deﬁcits in
social cognition – in view of their mutually detrimental
impact on the real-world function of patients (Section 2.3).
It would be difﬁcult to cover every single facet of NS in a
single tome, yet the majority of core issues are discussed in this
Special Volume which, in addition to this introductory synthesis,
contains a balanced selection of papers focussing on comple-
mentary clinical and preclinical aspects of NS, their character-
isation, pathophysiological substrates, potential treatment and
experimental study. The clinical section embraces 5 papers
which: focus on the core features and signiﬁcance of NS in
schizophrenia compared to other disorders (Foussias et al.,
2014); provide a historical perspective on NS (Malaspina et al.,
2014); describe established and novel procedures used to
measure NS in humans, including clinical trials (Marder and
Kirkpatrick, 2014); analyse mechanisms underlying the disrup-
tion of motivation and anticipatory pleasure (Kring and Barch,
Table 1 Characteristics of the ﬁve major sub-domains of negative symptom.
Sub-domain (alternative terms) Core characteristics
Blunted affect (affective ﬂattening,
blunted expression)
Reduced intensity and range of emotional expression as manifested via vocal and
non-verbal modes of communication including intonation (prosody), facial
expression, hand-gestures and body movements.
Alogia (poverty of speech) Decreased quantity of speech, reduced spontaneous speech and loss of
conversational ﬂuency.
Amotivation (loss of volition) Deﬁcits in the initiation and maintenance of goal-directed behaviours like work,
study, sport, personal hygiene and daily tasks, especially when requiring an effort
(cognitive or physical) and signiﬁcant organisation. Also deﬁcits in desire to
undertake such activities. Related to apathy and lack of energy.
Anhedonia (reduced ability to
experience or anticipate pleasure)
The looking forward to a reward, recreational or other pleasurable experience
(“wanting”) is more markedly and consistently impaired (anticipatory anhedonia)
than the appreciation (“liking”) of the experience itself (consummatory
anhedonia).
Asociality (social withdrawal) Diminished interest in, motivation for, and appreciation of social interactions with
others, like family and friends. Also, loss of interest in intimate (sexual)
relationships independent of any somatic problems. For children, may correspond
to loss of interest in playing together.
Deﬁcits indicated are mainly based on a NIMH consensus document (Kirkpatrick et al., 2006) which has been highly inﬂuential in
orienting research and diagnosis over recent years. As outlined in the text and discussed in detail in this Special Volume (Foussias
et al., in press; Malaspina et al., in press; Marder and Kirkpatrick, in press), there is an emerging consensus, tacitly recognised in DSM-
5 and supported by factor analysis, of two sub-clusters of negative symptoms. They comprise: (1) Diminished emotional expression
(incorporating blunted affect and – though not explicitly mentioned in DSM-5 – alogia) and (2) avolition (encompassing amotivation,
anticipatory anhedonia and asociality). Note that, as compared to poverty of speech itself, impoverished content of speech is now
usually integrated into disorganisation, another core domain of schizophrenia speciﬁed in DSM-5 (Figure 3). There is a certain degree
of overlap and interplay between the ﬁve domains: for example, asociality is partially attributable to low social motivation. Further,
certain facets of blunted affect, like loss of appropriate speech intonation (prosody) and deﬁcits in non-verbal communication, are
also inherent to an impairment of social cognition (Section 2.3).
M.J. Millan et al.6482014); and discuss the inﬂuence on NS of currently-available
antipsychotics and newer agents under clinical exploration
(Davis et al., 2014). The preclinical section is subdivided into
two subsections. First, readouts for evaluating NS: namely,
measures of motivation and reward (Barnes et al., 2014), and
procedures related to social interaction (Wilson and Koenig,
2014). Second, rodents models for (not of) schizophrenia in
which NS-like behaviours have been described, including
pharmacological (Neill et al., 2014), genetic (O’Tuathaigh
et al., 2014) and developmental (Moser, 2014) paradigms.
As regards this integrative and introductory paper, it has
several objectives. First, to set the scene in summarizing
the general features of schizophrenia and its current
management, to provide a global overview of the core
facets of NS, and to emphasise challenges and opportunities
for their improved understanding and control. Second, to
speciﬁcally review one major theme that intersects with all
other chapters yet which is not the topic for any single
article. That is, the cerebral circuits and neurochemical
substrates underling discrete sub-domains of NS as char-
acterised by structural and functional imaging in humans,
as well as electrophysiological and other analytic technol-
ogies (Section 3). Third, to interlink the separate contribu-
tions of this Volume via a mechanistic framework in which a
disruption of frontocortico-temporal and frontocortico-
striatal networks, as well as glutamatergic, GABAergic,
dopaminergic and oxytocinergic transmission, provides a
unifying theme. Fourth, to highlight a number of key topicsevoked in the separate articles, and to present some
additional aspects not covered elsewhere. Fifth, to discuss
prospects for the improved management of NS, with a
special emphasis on: (1) Novel pharmacotherapeutic
mechanisms, (2) alternative “stimulation” and “cognitive-
behavioural-psychosocial” strategies, and (3) the more
reﬁned, innovative and broader exploitation of experimen-
tal models and readouts for the study of NS. Finally, the
present paper incorporates some very recently-published
articles (up to March 2014) not otherwise cited in this
Special Volume.
2. Clinical studies of negative symptoms:
characteristics, prevalence and measurement
2.1. Historical background and core features of
negative symptoms up to and including DSM-5
As discussed herein by Malaspina et al. (2014), NS have a
long pedigree in schizophrenia stretching back to the Ger-
man pioneers of Kraepelin and Bleuler, 19th/early 20th
Century English, French and American schools of thought
and ultimately perhaps – through Avicenna – to the Hippo-
cratic canon and the father of brain and mind, Alcmaeon of
Kroton (Doty, 2007). In discussing “dementia praecox” (the
forerunner term for schizophrenia), Kraepelin was particu-
larly struck by NS-like features of indifference, emotional
649Negative symptoms of schizophreniadeﬁcits and, in particular, a lack of volition (Zec, 1995).
Somewhat later, Bleuler (who coined the term schizophre-
nia) asserted the ability to feel emotion was intact despite a
lack of will to seek it out – reminiscent of “anticipatory
anhedonia” (Section 3.3) (Heckers, 2011). He felt that these
changes were driven by a core, fundamental and pathophy-
siological process of disconnectivity (poor associations) of
thought and language (Heckers, 2011; Malaspina et al.,
2014). Nonetheless, probably unbeknown to Kraepelin and
Bleuler, the notion of “NS” (and positive symptoms) had
been foreshadowed by the 19th English neurologist, Rey-
nolds, who, in reference to epilepsy, distinguished symp-
toms like anaesthesia (loss) from others like spasms (gain)
(Messinger et al., 2011).
By analogy, and some 150 years later, in contrast to the
positive symptoms of schizophrenia (where delusions and
hallucinations etc. are “added”), the term “negative”
implies the loss of behaviours, interests, motivation and
desires as incarnated by avolition, and “diminished expres-
sion” (Table 1). As originally conceptualised by Carpenter
et al. (1988), it is desirable (though not always easy) to
differentiate primary NS inherent to the disease process
itself from secondary NS which may be a consequence
of social exclusion, lack of environmental stimulation, a
treatment-provoked extrapyramidal syndrome or co-morbid
depression etc. (Figure 2) (Foussias et al., 2014; Kaiser
et al., 2010; Kirkpatrick et al., 2006). It has been suggested
that a “deﬁcit syndrome” associated with a particularly
poor outcome and comprising predominately NS can be
found in certain drug-naïve patients at the time of admis-
sion, and in perhaps a third of chronic schizophrenics(Primary)
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Figure 2 Induction and aggravation of negative symptoms
by diverse factors related to schizophrenia. Primary NS are
inherent to the pathophysiology of schizophrenia, in much the
same way as positive symptoms. However, positive symptoms
themselves (suspiciousness and paranoia) – as well as other
cardinal feature of schizophrenia – may exacerbate NS. Further,
secondary NS – or a phenotype resembling primary NS – can be
provoked by auxiliary factors like the extrapyramidal side-
effects of neuroleptics, co-morbid depression or even a lack
of environmental stimulation. Thus, NS in patients may actually
reﬂect multiple causes and comprise a composite of primary
and secondary forms which are hard to differentiate.(Figures 1 and 2). Though the status of this “deﬁcit” entity
remains somewhat contentious, it is not disputed that many
patients display enduring and predominant NS: their inclu-
sion into clinical studies of NS has proven fruitful in the
exploration of neurobiological substrates and potential
control (Sections 3 and 4) (Beck et al., 2013; Buchanan,
2007; Carpenter et al., 1988, 1999; Kaiser et al., 2010;
Kanahara et al., 2013; Kirkpatrick et al., 2001; Nakaya and
Ohmori, 2008; Peralta and Cuesta, 2004; Peralta et al.,
2014).
While NS are ﬁrmly established in the ﬁrmament of
schizophrenia as a core domain of dysfunction (Blanchard
and Cohen, 2006; Blanchard et al., 2011; Buchanan, 2007;
Messinger et al., 2011), their composition has evolved
signiﬁcantly, and not always consistently, over the last 30–
40 years or so. One important landmark was the National
Institute of Mental Health (NIMH), treatment-oriented con-
sensus statement of 2005 (Kirkpatrick et al., 2006). This
document enshrined the following core domains, four of
which are preﬁxed by “a/an”, underpinning the above-
mentioned notion of “loss”: anhedonia, asociality, avolition,
alogia, and blunted affect (Table 1) (Messinger et al., 2011).
It is worth noting that the additional facet of impaired
attention (Andreasen, 1982, 1989) was shunted to the
sphere of neurocognition where it has become the focus
of a complementary NIMH-coordinated initiative to improve
neurocognitive deﬁcits and impaired social cognition in
schizophrenia (Buchanan et al., 2011b; Carter and Barch,
2007; Millan and Bales, 2013). While DSM-III tended to
neglect negative vs positive symptoms (except for poverty
of speech), both avolition and ﬂat affect made their
entrance in the revised version DSM-IIIR. Later on, around
the turn of the millennium, DSM-IV placed NS on centre
stage of the agenda with the recognition of avolition, alogia
and blunted affect.
The latter points are thoughtfully discussed by Malaspina
et al. (2014) in this volume, who also emphasise that the
diagnostic goalposts appear to be moving again with the
advent of DSM-5 (Figure 3) (Blanchard et al., 2011; Barch
et al., 2013; Heckers et al., 2013; Tandon et al., 2013). In this
recently-released tome, NS comprise one of the ﬁve “deﬁn-
ing” domains of schizophrenia (or schizophrenia spectrum
disorder) together with hallucinations (auditory and other
sensory sensations not rooted in the outside world), delusions
(beliefs detached from reality), disorganised speech (incoher-
ent verbal language) and abnormal psychomotor function
(bizarre behaviours and catatonia). In addition to three further
(though not “deﬁning”) diagnostic dimensions (depression,
mania and cognition), NS and the other four core domains of
schizophrenia are semi-quantiﬁable on a scale of 0–4, which
should facilitate their assessment and comparison. In the DSM-
5 canon, NS are considered to be (1) avolition, embracing
decreased motivation, asociality and anticipatory anhedonia
and (2) diminished emotional expression, incorporating
blunted affect and – implicitly – alogia (poverty of speech)
(Table 1). Avolition would be apparent from, for example,
a lack of goal-directed and self-initiated behaviours while
restricted emotional expression would be revealed by a
poverty of speech and non-verbal (paralinguistic) communica-
tion like facial expressions and hand gestures (Blanchard
et al., 2011; Barch et al., 2013; Heckers et al., 2013;
Tandon et al., 2013).
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Figure 3 Negative symptoms as one of the ﬁve diagnostic
pillars of schizophrenia in DSM-5. DSM-5 has identiﬁed ﬁve
“deﬁning” symptoms for the diagnosis of schizophrenia, which
should become apparent in the course of appropriate observa-
tion and interviews. One of these is NS, together with halluci-
nations and delusions (positive symptoms), psychomotor
dysfunction (agitation, retardation, catatonia) and disorganisa-
tion. Depressed mood, mania and cognitive impairment (which
subsumes impaired social cognition) are additional criteria to
be considered, but they are not diagnostic per se. Note that
neurocognitive dysfunction usually requires the use of speciﬁc
tests for its characterisation as opposed to impairment in social
cognition and NS which should be apparent during the course of
the interview and from other forms of interaction.
M.J. Millan et al.650Importantly, this lack of non-verbal expression, together
with impaired prosody (intonation in speech), intersects
with deﬁcits in social cognition (Section 2.3). On the other
hand, the “anhedonia” of NS does not, in contrast to
depression (a separable domain), principally reﬂect an
ability to experience pleasure (“liking”). Rather, it conforms
to deﬁcient anticipation of pleasure (“wanting”) as
reﬂected in a lack of coordinated behaviour and effort
dedicated to its attainment (Section 3.3) (Berridge et al.,
2009; Berridge and Kringelbach, 2013; Der-Avakian and
Markou, 2012; Strauss et al., 2014) – evocative of the
Kraepelian notion of impaired volition (Foussias et al.,
2014; Gard et al., 2007; Huxley and Fonseca, 2014; Kaiser
et al., 2010; Zec, 1995; Kring and Barch, 2014; Kring and
Elis, 2014; Wynn et al., 2010 – but see Konstantakopoulos
et al., 2011). Anticipatory anhedonia is medication-
independent and apparent both at ﬁrst episode and in the
chronic phase of the disorder (Nielsen et al., 2012; Yee
et al., 2010). This issue is carefully analysed by Foussias
et al. (2014), and by the complementary article of Kring and
Barch (2014), in this Special Volume.
These authors likewise discuss the reasoning underlying
the growing (and DSM-5 reinforced) conviction of two
interrelated yet distinguishable sub-clusters of NS: avolition
and diminished emotional expression. This notion harks back
to the NIMH consensus document evoked above (Kirkpatrick
et al., 2006) and to the analysis made around this time of
Blanchard and Cohen, 2006. Then, and in many subsequent
studies (Foussias et al., 2014; Mehta et al., 2011), the ﬁvenegative symptom domains summarised in Table 1 could
mostly be accounted for by the robust and independent
factors of decreased emotional expression and avolition.2.2. Measurement of NS: established and novel
rating scales
The above-mentioned distinction has been further rein-
forced by recent work and, as articulated by Malaspina
et al. (2014) and Marder and Kirkpatrick (2014) in this
Special Volume, ﬁnds expression in the recent development
of new rating scales for identiﬁcation, characterisation and
quantiﬁcation of NS – both in the context of diagnosis and,
importantly, of clinical trials. Deserving of special mention
are the NIMH-linked CAINS (Clinical Assessment Interview
for Negative Symptoms) and the somewhat shorter (time to
complete) and already-translated BNSS (Brief Negative
Symptom Scale) which: (1) share similar organisation,
(2) display excellent test/re-test reliability and (3) provide
support for the two-factor concept of deﬁcits in motivation
vs blunted affect. These new instruments represent signiﬁ-
cant advances compared to older scales like the composite
and widely-used: (1) Positive and Negative Symptoms Scale
(PANSS), of which the relevant subscale fails to fully cover
the whole gamut of NS and (2) Scale for Assessment of
Negative Symptoms (SANS) which, like the PANNS, incorpo-
rates attentional deﬁcits, and conﬂates observations over a
one month period limiting its sensitivity to detect rapid
change (Harvey et al., 2006; Horan et al., 2011; Kirkpatrick
et al., 2011; Kring et al., 2013; Malaspina et al., 2014;
Marder and Kirkpatrick, 2014). The respective merits – and
limitations – of these innovative scales will become clearer
in the course of their broader utilisation. In any event, they
should permit the more sensitive and rigorous characterisa-
tion of NS, with the differentiation of the two above-evoked
sub-domains likely related to contrasting neurobiogical
substrates (Section 3). This should, in turn, facilitate the
clinical evaluation of new and potentially-improved medi-
cation for NS (Section 4). Supporting this contention,
Strauss et al., 2012, 2013, for example, recently reported
two subpopulations that showed contrasting proﬁles of
impaired avolition yet essentially intact expression and vice
versa.
Three ﬁnal yet important points – not enitrely resolved to
date by any particular scale per se – should brieﬂy be
evoked. These are the issues of, ﬁrst, differentiating
primary NS inherent to the disorder from secondary NS
(vide supra). Though reducing NS by avoiding motor side-
effects and alleviating co-morbid depression is obviously
desirable, novel medication should be designed to speciﬁ-
cally relieve debilitating, primary NS. The second and
related issue is distinguishing a symptom from a cause and
from an outcome. Social withdrawal, for example, is an
expression of asociality and decreased (social) motivation,
yet also a consequence of impaired social cognition and a
contributory factor to depressed mood. This leads to a third
and interrelated remark that NS may have several, conver-
ging causes: in the case of social withdrawal, a lack of social
motivation, deﬁcits in social cognition and social anxiety.
This multiple causation is reﬂected in the implication of
diverse neural substrates discussed in Section 3.
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impaired social cognition
The concluding point of the previous paragraph brings up
the more general, complex and incompletely resolved
matter of the interplay between NS and other core domains
of dysfunction in schizophrenia in terms of patient pheno-
type, underlying neurobiological substrates and potential
treatment strategies (Figure 4).
Though normal neurocognitive performance is beneﬁcial for
appropriate social cognition, these are distinct domains of
function, both of which are impaired in schizophrenia (Bliksted
et al., 2014; Brown et al., 2012; Bora et al., 2009; Brüne, 2005;
Fanning et al., 2012; Green et al., 2008, 2012; Hoe et al., 2012;
Mehta et al., 2013; Millan et al., 2012). In fact, rather than
impaired neurocognition, it is the interface between deﬁcits in
social cognition and NS that is the most noteworthy and
complex to comprehend since, while distinct, they interact.
NS are driven by impaired social cognition which, at least
partially, intervenes in its deleterious impact on functional
outcome (Figure 4) (Foussias et al., 2014; Harvey et al., 2006;
Kaiser et al., 2010; Lincoln et al., 2011; Mehta et al., 2013;
Sergi et al., 2007).
As brieﬂy mentioned above, social cognition refers to the
suite of cerebral mechanisms and mental operations used toNeur
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M.J. Millan et al.652social cognition – in addition to social anxiety (Pallanti
et al., 2004; Romm et al., 2011; Voges and Addington,
2005). Second, reduced facial expression, body movements
and hand gestures are core elements of NS (diminished
emotional expression), yet the enactment of these modes of
non-verbal communication, just as much as their interpre-
tation, are usually taken as fundamental components of
social cognition (Frith and Frith, 2012; Millan et al., 2012).
One approach to resolving this paradox might be to
consider social cognition as purely concerned with the
reception and interpretation as opposed to the perfor-
mance and emission of social signals. For the present
purposes, the critical point is that impaired social cognition
not only aggravates positive symptoms like paranoia, suspi-
ciousness and delusional thinking, but also contributes to
and drives NS (Figure 4). This is important since NS and
impaired social cognition collectively have the most serious
impact upon the functional status of patients: correspond-
ingly, they are correlated with poor outcome throughout the
entire course of schizophrenia (Figure 1) (Corcoran et al.,
2011; Foussias et al., 2014; Lincoln et al., 2011; Maat et al.,
2012; Mehta et al., 2013; Sergi et al., 2007).2.4. Relationship of negative symptoms to other
classes of symptom
The consummatory anhedonia of depression is, as men-
tioned above, distinct to the anticipatory anhedonia seen in
schizophrenia. Nonetheless, co-morbid depression may well
exacerbate NS by directly compromising hedonic states, and
further delimiting effort-linked cognitive and motor perfor-
mance aimed at acquiring reward (Harvey et al., 2009;
Huxley and Fonseca, 2014; Kaiser et al., 2010; Millan et al.,
2012; Salamone et al., 2012). In a broad sense, anxiety is
very prevalent in schizophrenia: in addition to co-morbid
anxious states, anxiety can be provoked by psychotic
episodes and aversion to medication. Social anxiety is
particularly common: it may speciﬁcally contribute to social
withdrawal, or itself be provoked and aggravated by a lack
of social motivation (Figure 4) (Pallanti et al., 2004; Romm
et al., 2011; Voges and Addington, 2005).
As pointed out elsewhere (e.g., Messinger et al., 2011),
positive symptoms may drive asociality and other facets of
NS due to extreme suspiciousness and paranoia. As for
neurocognitive deﬁcits, many authors have discussed their
interrelationship with NS, and Foussias et al. (2014) con-
sidered the possibility that their impact on functional
outcome is mainly mediated via NS – and impairment of
social cognition (Figure 4) (Harvey et al., 2006; Hoe et al.,
2012; Lin et al., 2013; Nakagami et al., 2008; Ventura et al.,
2009). Moreover, Kring and Barch (2014) and Barnes et al.
(2014) evoked the signiﬁcance of compromised executive
function and top-down cognitive control (Lesh et al., 2011;
Millan et al., 2012) to the defective goal-directed acquisi-
tion of reward seen in schizophrenia (Section 3.3). While
attentional deﬁcits have, as mentioned above, been
detached from NS, this should not detract from the point
that impaired attention will deleteriously impact mechanisms
sustaining the attainment of reward and social engagement
(Figure 4) (Der-Avakian and Markou, 2012; Harvey et al.,
2006). In addition, intact episodic memory (remembering,recall, and prospective cognition) (Schacter et al., 2007;
Millan et al., 2012) is required for appropriate social inter-
action and estimation of future reward values (Section 3.3).
Reciprocally, avolition can impact multiple domains of neu-
rocognition – not least the performance of cognitive tests
during clinical trials (Nakagami et al., 2008; Millan et al.,
2012).
Finally, it is hard to imagine that the poor content of
speech and loss of verbal ﬂuency in schizophrenia (a feature
of disorganisation) (Figure 3) is entirely unrelated to the
poverty of speech, itself a sub-domain of NS (Table 1) (Fitch
et al., 2010; Frith and Frith, 2012; Millan et al., 2012).
In light of the above remarks, it is instructive to consider
NS not in isolation, but rather in relation to other prominent
and interacting symptoms of schizophrenia (Figure 4).
2.5. Relationship of negative symptoms to
functional impairment throughout the lifespan
of schizophrenia
In view of the deleterious impact of NS on real world
function, it is important to note their occurrence through-
out the disorder, not just in medicated, chronic, remitting-
relapsing subjects, but around the ﬁrst episode and even in
the prodrome (Figure 1) (Boonstra et al., 2012; Corcoran
et al., 2011; Demjaha et al., 2012; Fusar-Poli et al., 2013a;
Green et al., 2012; Hovington et al., 2012). Together with
impaired social cognition, co-morbid depression and disor-
ganisation, NS are prominent and disabling in at-risk,
prodromal adolescents and young adults (Corcoran et al.,
2011; Fulford et al., 2013; Fusar-Poli et al., 2013a, 2014;
Piskutic et al., 2012). The sub-domains of NS that most
disrupt for normal life, social integration and academic
achievements in at-risk subjects are uncertain, but intui-
tively a lack of social motivation is likely to be especially
incapacitating.
The presence of NS during the prodrome supports the
notion of their primary nature and suggests that NS and
their neural substrates may even be a driver (like impaired
social cognition) of transition to psychosis (Figure 4).
Correspondingly, it may be hypothesised that treatments
alleviating NS – and impaired social cognition/neurocogni-
tion – in high-risk young subjects would both alleviate
suffering and reduce the risk of transition to schizophrenia
– and other serious psychiatric disorders (Fusar-Poli et al.,
2013a; Lewis, 2012; Miyamoto et al., 2012; Millan et al.,
2012; Sabbag et al., 2011).
2.6. Negative-like symptoms in other psychiatric
and neurological disorders
The present issue focuses exclusively on schizophrenia but it
is worth accentuating, as exempliﬁed in the article of
Foussias et al., 2014, that NS-like symptoms are present in
several other psychiatric and neurological disorders. This
mirrors the occurrence of deﬁcits in social cognition across a
broad range of psychiatric and neurological conditions
(Millan et al., 2012) and emphasises that NS alone cannot
per se be considered as diagnostic for schizophrenia
(Figure 3) (Barch et al., 2013; Tandon et al., 2013). It has
been claimed that NS (including apathy) are manifest in
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they are distinct from consummatory pleasure (anhedonia)
(Bottlender et al., 2003; Huxley and Fonseca, 2014). Apathy
is also prominent in Parkinson's and Alzheimer's disease and,
in the latter case, correlates with the magnitude of
dementia (Chase, 2011; Levy and Dubois, 2006; Millan,
2010; Mitchell et al., 2011; Starkstein et al., 2009). Mirror-
ing schizophrenia, the presence of NS in these disorders is
associated with poor functional status, and conventional
medication is largely ineffective (op. cit).
Certain mechanisms underlying NS may be similar
between schizophrenia and other disorders, such as the
anomalous operation of cortico-striatal mechanisms of
reward, yet others will inevitably differ (Berridge and
Kringelbach, 2013; Gradin et al., 2011; Kring and Barch,
2014; Simon et al., 2010). For example, the implication of
anomalous dopaminergic signalling in the apathy of both
schizophrenia and Parkinson's disease deserves mention, as
well as a role for dysfunctional circuits linking the PFC and
the basal ganglia (Section 3) (Chase, 2011; Levy and Dubois,
2006; Starkstein et al., 2009). Conversely, as regards
anhedonia, the perturbation of mesolimbic dopaminergic
transmission in major depression can be differentiated from
its deregulation in schizophrenia (Section 3.3) (Millan, 2006;
Remington et al., 2011). Further, despite the fact that
aberrant function of the PFC is incriminated in the apathy of
schizophrenia and Alzheimer's disease (Section 3.2), the
functional breakdown of frontocortico-temporal coupling in
schizophrenia (Section 3.1) can be distinguished from the
progressive β-amyloid and tau-driven processes of neuronal
neurodegeneration that damage the temporal lobe and
entorhinal cortex in Alzheimer's disease (Chase, 2011;
Mitchell et al., 2011; Stella et al., 2014).
Importantly, common patterns of NS-like symptoms – and
pathophysiological substrates – amongst schizophrenia and
other diseases accentuate the relevance of a trans-
nosological perspective in the study and ultimately control
of multi-factorial and heterogeneous disorders like schizo-
phrenia (Cuthbert, 2014; Millan et al., 2012). An agent
found to alleviate NS in schizophrenia might emerge to have
broader utility in the treatment of NS-like symptoms in
other psychiatric and neurological disorders.3. Neural and neurochemical substrates of
negative symptoms
3.1. Cortico-subcortical circuits implicated in NS:
general considerations
By analogy to Alzheimer's disease, there has been some
debate as to whether schizophrenia might, at least partially,
be a neurodegenerative-like disorder, with “neurotoxic”
repercussions of the disease process itself progressively
damaging the brain in a manner, either inhibited by,
resistant to, or even exacerbated by antipsychotics
(Archer, 2010; Fusar-Poli et al., 2013b; Rund, 2009). None-
theless, there is overwhelming evidence that schizophrenia
is principally a disorder of neurodevelopment triggered by a
panoply of genetic, epigenetic and environmental factors,
providing a the foundation for animal models discussed inSection 5 (Archer, 2010; Fatemi and Folsom, 2009; Millan,
2013; Puri, 2010; Rapoport et al., 2012).
Regardless of causation, as described below, like other
facets of schizophrenia, NS likely reﬂect anomalies of
distributed neural networks rather than the disruption of
any discrete brain region (Figure 5). The corresponding
structural and functional changes are well-established at
the time of the ﬁrst psychotic episode, and they actually
anticipate diagnosis bring prominent in high-risks subjects
prior to transition (Section 2.5): further, they continue to
progress throughout the course of the disorder, notably as
regards changes in the frontal and temporal lobes (Fusar-
Poli et al., 2012, 2013b; Nakamura et al., 2013; Puri, 2010;
Vita et al., 2012).
Many investigations have compared patients displaying
persistent and predominant NS to those without them, or
studied patients with a “deﬁcit syndrome” (Section 2.1)
(Carpenter et al., 1988, 1999; Buchanan, 2007; Kaiser et al.,
2010; Kirkpatrick et al., 2001), in order to pinpoint the key
circuits impacted. As regards techniques exploited, structural
Magnetic Resonance Imaging (MRI) imaging permits visualisa-
tion of alterations in the grey matter volume of speciﬁc brain
structures, Diffusion Tensor Imaging has been employed to
examine the disruption of white matter tracts, and functional
neuroimaging – mainly functional MRI (fMRI), but also Single
Photon Emission Computerised Tomography (SPECT) – has been
applied to probe the alterations in neuronal activity of
discrete brain regions in relation to NS.
Several studies of schizophrenia outlined below have
focussed on the resting and self-referential “default mode
network”, which deactivates during goal-directed activity –
such as the organised acquisition of a reward (Broyd et al.,
2009; Mazza et al., 2013; Orliac et al., 2013; Park et al.,
2009; Whitﬁeld-Gabrieli and Ford, 2012). Nonetheless, most
fMRI work has been undertaken employing cognitive tasks,
of which certain – like executive function – are coordinated
by cortico-subcortical networks dysfunctional in NS. In
addition, studies of blunted affect have tended to exploit
emotionally-charged (and erroneously interpreted) stimuli
to determine the sites of anomalous cerebral activity in
schizophrenia (Barch and Dowd, 2010; Dowd and Barch,
2010; Goghari et al., 2010; Hovington and Lepage, 2012).
For all studies, despite an increasing tendency to perform
work early in the disorder and in subjects with predominant NS,
it is still difﬁcult to isolate changes directly related to NS vs
those coupled to other symptoms, in particular as regards
impaired social cognition (Section 2.3). Studies have been
undertaken in drug-naïve subjects, but medication remains an
obvious confound: in this case, an attractive option is to
examine its potential reversal of putative anomalies (Barch
and Dowd, 2010; Benoit et al., 2012; Filippi et al., 2014;
Goghari et al., 2010; Hovington and Lepage, 2012; Kring and
Barch, 2014; Stip et al., 2005; Strauss et al., 2014).
As regards the interpretation of data, it should not
automatically be assumed that alterations are causal to
NS: changes may be merely correlated (epiphenomon) or
even provoked by NS themselves. Alternatively, they may be
compensatory in an effort to counter the deleterious impact
of NS, as suggested for cannibinoids (Section 3.7) (Ceccarini
et al., 2013) and exempliﬁed by observations in schizo-
phrenics that certain brain regions are over-activated in
cognitive, emotion-processing and motor procedures in an
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M.J. Millan et al.654attempt to offset the failure of structures that fail to
respond (Bracht et al., 2014; Koike et al., 2013; Taylor
et al., 2012; Unschuld et al., 2014). Moreover, from a trans-
nosological perspective, it is still unclear which cerebral
mechanisms implicated in the NS of schizophrenia are
entirely distinct from those incriminated in the NS-like
dysfunction of other disorders (Section 2.5). Finally, patho-
physiological mechanisms incriminated in the genesis of NS
are not necessarily synonymous with those that maintain
them once established.
Despite these caveats, and sometimes marked variability
between the ﬁndings of speciﬁc studies, data from com-
plementary structural, imaging and electrophysiological
approaches have converged in incriminating several pivotal
networks and cerebral structures in NS. Further, the con-
clusions of studies in patients are globally in line with
experimental work discussed below, despite the – to date
– limited application of imaging to rodents (Section 5).
As outlined below, fronto-temporal and frontocortico-striatal
circuits are the most consistently and robustly implicated in
NS – though not exclusively – but the roles of their speciﬁc
sub-regions differ amongst distinct sub-domains of NS.
It is instructive to initially summarise overall ﬁndings for
the temporal and frontocortical lobes before focussing onstructures more speciﬁcally implicated in the different sub-
domains of NS. The dysfunction of neural networks involved
in anticipatory anhedonia is particularly complex and
authoritively analysed by Kring and Barch (2014) in this
Special Volume. Consequently, this rich and specialised body
of the literature is only succinctly summarised below.3.2. Anomalies of cerebral structures implicated
in NS: structural and functional characterisation
3.2.1. Temporal lobes: structural imaging
A decrease in the grey matter volume of the temporal lobe,
in particular the superior temporal gyrus, has been asso-
ciated with NS with striking consistency (Benoit et al., 2012;
Cascella et al., 2010; Fischer et al., 2012; Fusar-Poli et al.,
2012, 2013b; Galderisi et al., 2008; Hovington and Lepage,
2012; Sanﬁlipo et al., 2000; Vita et al., 2012; Yamasue
et al., 2004). Interestingly, the temporal gyri lie at the
heart of circuits involved in social cognition, including
facial/gaze processing and, for the superior temporal gyrus,
Theory of Mind – and this region is also integral to networks
integrating language (Adolphs, 2009; Carrington and Bailey,
2009; Millan et al., 2012; Millan and Bales, 2013; Rushworth
655Negative symptoms of schizophreniaet al., 2013). These observations are consistent with the
reduced verbal expression (alogia) of NS and underscore the
interrelationship of NS with impaired social cognition, though
temporal lobe anomalies are also related to other features of
schizophrenia, like positive symptoms and disorganisation
(Goghari et al., 2010).
The temporal lobe is strongly interconnected with the
frontal lobes, and both structural studies of white matter –
and electrophysiological recordings (Section 3.2.4) (Kim
et al., 2014, Thoma et al., 2005) – suggest that the
disruption of this connection is related to the genesis of
NS. For example, the uncinate fasiculus links the temporal
lobe to the orbitofrontal cortex (OFC), and its disturbance
in schizophrenia has been related to NS, perhaps due to
interrupted exchange of information concerning reward
value and history (Kitis et al., 2012; S.H. Lee et al., 2013;
Nestor et al., 2013; Voineskos et al., 2013; Von Der Heide
et al., 2013).
There is, then, a compelling set of observations linking
dysfunction of the temporal lobe to NS, most likely as
regards asociality and blunted affect (especially alogia) and
perhaps also as concerns the elements of time and memory
for predicting reward, though this remains to be directly
demonstrated.3.2.2. Frontal lobes: structural imaging
As for the frontal lobes themselves, a rather disparate
pattern of grey matter reductions has been found in various
sub-regions (Hovington and Lepage, 2012).
Regions where deceases in grey matter have been reported
include the inferior frontal gyrus – a core component of social
cognition (Adolphs, 2009; Millan et al., 2012) – and both the
OFC and anterior cingulate, with a probable link to aberrant
mechanisms of reward (Bergé et al., 2011; Filippi et al., 2014;
Galderisi et al., 2008; Nakamura et al., 2013; Nestor et al.,
2013; Sanﬁlipo et al., 2000; Schobel et al., 2009; Stip et al.,
2005; Takayanagi et al., 2010, 2013; Yamasue et al., 2004).
Conversely and counter-intuitively, despite its implication in
deﬁcient goal-directed behaviour required for reward acquisi-
tion (Kring and Barch, 2014), the dorsolateral PFC (DLPFC) has
shown only modest and variable changes in volume: moreover,
putative changes are not necessarily correlated with NS,
rather to cognitive dysfunction (Baaré et al., 1999; Behere,
2013; Benoit et al., 2012; Fischer et al., 2012; Galderisi et al.,
2008; Hovington and Lepage, 2012; Schobel et al., 2009; Stip
et al., 2005; Takayanagi et al., 2010; Volpe et al., 2012).
A rather robust observation is a reduction of white
matter, correlated with the severity of NS and suggesting
reduced connectivity: (1) amongst sub-territories of the
PFC, (2) between the PFC and other cortical regions like the
temporal, insular and occipital cortices (see above) and (3)
to sub-cortical structures like the striatum (see below)
(Bracht et al., 2014; Cascella et al., 2010; Galderisi et al.,
2008; Hoe et al., 2012; S.H. Lee et al., 2013; Voineskos
et al., 2013; Zetzsche et al., 2008).3.2.3. Temporal and frontal lobes: functional imaging
Reinforcing structural data presented above, functional
imaging has visualised temporal lobe anomalies linked to
NS, including hypoactivity and a greater rightward symmetry:
aberrant operation of the temporal lobe is also suggested bythe poor performance of schizophrenics in neuropsychologi-
cal tests involving the temporal cortex. In addition, NS are
correlated with reduced connectivity of the superior tem-
poral gyrus to frontocortical regions like the anterior cingu-
late (Benoit et al., 2012; Cohen et al., 2007; Ke et al., 2010;
Millan et al., 2012; Potkin et al., 2002).
As concerns the PFC itself, several studies suggest that a
dysfunction of the default mode network involving the
ventromedial PFC is correlated with NS (Mazza et al.,
2013; Orliac et al., 2013; Park et al., 2009), and possibly
defective verbal expression (Bluhm et al., 2007; Whitﬁeld-
Gabrieli and Ford, 2012). Further, there are reports of
abnormal activity in the OFC and anterior cingulate,
changes blunted by antipsychotics (Kanahara et al., 2013;
Stip et al., 2005). Similar alterations have been seen in the
insula, and its interaction with the anterior cingulate
appears to be disrupted in schizophrenia (Figure 5)
(Gradin et al., 2013; Manoliu et al., 2013).
Mirroring ﬁndings with structural studies evoked above,
and in contrast to the ventromedial PFC (Figure 5), fMRI
studies have not invariably found an association between NS
and decreased operation of the DLPFC: disruption of this
region and its interaction with the striatum seems more
strongly linked to disorganisation and cognitive impairment,
notably of executive function (Ehrlich et al., 2012; Goghari
et al., 2010; Lesh et al., 2011; Van Veelen et al., 2010).
Goghari et al. (2010) carefully discussed these ﬁndings, and
suggested that putative deﬁcits in DLPFC activity may have
been normalised by antipsychotics in certain studies –
analogous to above-mentioned ﬁndings for the OFC and
anterior cingulate (Stip et al., 2005). Interestingly, disrup-
tion of DLPFC activity (and frontal lobe dysfunction in
general) was claimed to be predictive of the induction of
NS by ketamine (Honey et al., 2008). Clearly, the question
of how the apparent dysfunction of the DLPFC in schizo-
phrenia relates to NS awaits more reﬁned evaluation.
It should also be pointed out that alterations in the activity
and connectivity of the parietal cortex, including the pre-
cuneus – part of the default mode network (Whitﬁeld-Gabrieli
and Ford, 2012) – have been linked to the induction of NS
(Bluhm et al., 2007; Broyd et al., 2009; Goghari et al., 2010).
It is possible that these observations relate to the important
role of this region in social cognition (Adolphs, 2009; Millan
et al., 2012; Guo et al., 2014; Rushworth et al., 2013).
Thus, the interplay between NS on the one hand and
neurocognition-social cognition on the other can be hard to
determine. Nonetheless, structural and functional data
collectively indicate that a disruption of diverse sub-
territories of the temporal lobe and PFC, and of commu-
nication between the PFC, temporal and probably insular,
parietal and occipital lobes, is related to NS. As indicated
below, this is not to neglect the signiﬁcance of PFC coupling
to the basal ganglia, and the possible implication of other
structures like the thalamus and cerebellum (Ehrlich et al.,
2012; Goghari et al., 2010; Hovington and Lepage, 2012;
Pinault, 2011; Potkin et al., 2002).3.2.4. Cortical and sub-cortical circuits,
electrophysiological studies
Though perhaps less glamourous than imaging, non-
invasive electrophysiological (EEG) tools are invaluable for
M.J. Millan et al.656characterising the interrelationship between the activity of
speciﬁc cerebral circuits and functional domains perturbed in
schizophrenia like information-processing, mood and
cognition, (Boutros et al., 2013; Millan et al., 2012; Wang,
2010).
It was suggested that an impairment in the synchronous
operation of local vs global cortical circuits, including a loss
of gamma power, is speciﬁcally linked to NS (Noh et al.,
2013). This is interesting since the coordination of PFC-
driven glutamatergic networks by GABAergic interneurones
can be picked up in the gamma range (30–80 Hz): their
disruption in schizophrenia is related to abnormal, PFC-
integrated executive function and “top-down control”
which indirectly impacts NS (Figures 4 and 5) (Kring and
Barch, 2014; Stan and Lewis, 2012; Lesh et al., 2011; Millan
et al., 2012; Wang, 2010). Likewise of pertinence are
studies using spectral EEG that related increases in slower
rhythms, including episodic memory-related, frontocortico-
hippocampal theta (4–7 Hz), to the intensity of NS (Boutros
et al., 2013). Further, a decrease in delta slow wave sleep
has repeatedly been found to correlate with NS severity; it
appears to involve perturbation of thalamic projections to
the frontal lobes, emphasising that aberrant input to the
cortex from this key gating structure may participate in the
induction of NS (Pinault, 2011; Sekimoto et al., 2011).
The monitoring of Event Related Potentials (ERP) can also
yield insights into the integrity of cortical circuits in relation
to NS and to the risk of transition during the prodromal
phase (Boutros et al., 2013; Fusar-Poli et al., 2013a; Horan
et al., 2010). For example, several – though not all – studies
indicate that interference with the P300 “oddball” (unex-
pected stimulus) response is linked to NS: further, the most
marked reduction is seen over the parietal region in
patients with predominantly NS, as opposed to the temporal
lobe for those with less pronounced NS (Boutros et al., 2013;
Oribe et al., 2013; Ozgürdal et al., 2008). The P300 signal is
already aberrant in subjects at high risk for conversion
(Boutros et al., 2013; Fusar-Poli et al., 2013a). As another
example, studies of ERP have supported the above-evoked
relationship between fronto-temporal decoupling and NS
(Kim et al., 2014; Thoma et al., 2005).
The precise mechanistic foundations of links between
electrophysiological readouts on the one hand, and NS on
the other, is still uncertain, but these ﬁndings reinforce the
signiﬁcance of disruption of cortical and cortico-subcortical
networks to their genesis.3.3. Dysfunctional neural circuits related to
amotivation and anticipatory anhedonia
As emphasised in this Special Volume (Foussias et al., 2014;
Kring and Barch, 2014; Malaspina et al., 2014), the appre-
ciation of pleasure per se does not seem to be greatly
affected in schizophrenia, and consummatory anhedonia
(“liking”) appears to be dissociable from NS which are
coupled to compromised “wanting” (anticipatory anhedo-
nia) (Berridge et al., 2009; Berridge and Kringelbach, 2013;
Huxley and Fonseca, 2014). Imaging studies support this
interpretation, despite the fact that some variable changes
have been seen in fMRI studies of the response of the
cortex, striatum, cerebellum and amygdala to rewardingstimuli (Dowd and Barch, 2010; Barch and Dowd, 2010;
Goghari et al., 2010; Kring and Barch, 2014; Simon et al.,
2010).
By contrast to consummatory pleasure per se, imaging
studies in schizophrenics have consistently revealed anoma-
lies in processes related to the anticipation of reward
(anticipatory anhedonia), and to the motivation, effort,
approach behaviour and goal-directed actions requisite for
acquisition: they can primarily be attributed to abnormal
operation of the ventral striatum (nucleus accumbens) and
dorsal striatum (mainly the caudate) in interaction with the
PFC (Figure 5). For example, cues signalling reward are less
efﬁcient in activating the ventral striatum – and ventrome-
dial PFC/OFC – in schizophrenics (Dowd and Barch, 2012;
Juckel et al., 2006; Harvey et al., 2009; Nielsen et al., 2012;
Simon et al., 2010; Strauss et al., 2014; Waltz et al., 2009).
Other interlinked structures also appear to be involved, like
the anterior insular cortex which projects to the OFC and
ventral striatum and which is reciprocally interconnected
with the amygdala: it plays an important role in social
cognition, emotional processing, mood and reward, and
both its volume and functional activity is compromised in
schizophrenia (Section 3.1) (Millan et al., 2012; Manoliu
et al., 2013; Waltz et al., 2009; Yamasue et al., 2004), with
a speciﬁc link to the reward deﬁcits of NS (Croxson et al.,
2009; Dowd and Barch, 2010; Gradin et al., 2011).
Since the article of Kring and Barch (2014) in this Special
Volume (Section 5.6) critically analyses this sub-domain of
NS in detail, the core observations are only brieﬂy recapi-
tulated below and, for ease of comprehension, the major
circuits implicated are graphically presented in Figure 5.
See also Barnes et al. (2014) in this Special Volume for an
experimental perspective on this issue, and note that
anatomical and functional observations are not entirely
transposable across species.
The motivational deﬁcits accounting for anticipatory
anhedonia – or impaired anticipatory pleasure (desire) –
can be parsed into several, interrelated functions known to
be compromised in schizophrenia (Croxson et al., 2009;
Fervaha et al., 2013; Gold et al., 2013, Strauss et al., 2014;
Ward et al., 2012), and mediated by contrasting territories
of the PFC and striatum (Figure 5).
First, a core element of motivation is the perceived value
of the reward in relation to desires/needs. This may need to
be updated in the light of recent experience, and value
calculated in light of the delay to receipt (“delay discount-
ing”). The OFC – which plays a key role with the nucleus
accumbens in pleasure (Berridge and Kringelbach, 2013;
Kringelbach, 2005) – acts in interaction with the nucleus
accumbens and dopaminergic mechanisms to underpin these
functions (Deserno et al., 2013; Padoa-Schioppa and Cai,
2011). Both the function of the OFC and its interconnection
with the nucleus accumbens, as well as value computation
of reward, are perturbed in schizophrenia (Bracht et al.,
2014, Diekhof et al., 2012; Harvey et al., 2009; Levy and
Dubois, 2006; Morris et al., 2012; Strauss et al., 2014).
Faulty encoding of expected reward in schizophrenia (impli-
cated in apathy) involves, then, dysfunction of an OFC-
striatal network, though other DA-rich regions may also be
involved, like the insular cortex, amgydala and hippocam-
pus (Gradin et al., 2011; Kring and Barch, 2014; Levy and
Dubois, 2006).
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incur a (cognitive and/or physical) cost, the computation of
which is assumed by the anterior cingulate together with
(dopaminergic signalling in) the nucleus accumbens. Their
functional integrity is essential for a decision to opt for a
greater reward coupled to supplementary effort, and
patients with schizophrenia show both a disruption of the
anterior cingulate (Section 3.2) and of this function
(Botvinick et al., 2009; Croxson et al., 2009; Fervaha
et al., 2013; Gold et al., 2013, Strauss et al., 2013;
Treadway et al., 2009, 2012; Ward et al., 2012). Interest-
ingly, in a social environment, it may be necessary to
compete for reward, coupled to additional effort, and the
anterior cingulate likewise appears to be involved in option
selection in this context, one likely to be ﬂawed in schizo-
phrenia (Hillman and Bilkey, 2012). It should also be
mentioned that dysfunctional coupling between the ante-
rior cingulate and the insular cortex (“salience network”)
has been linked to the failure to appropriately process
reward in schizophrenia (Gradin et al., 2013).
Third, in the context of exploratory behaviour, a goal-
directed action must be engaged in order to obtain the
reward, This function appears to depend on the DLPFC
which, reﬂecting intrinsic dopaminergic, adrenergic and
other mechanisms related to executive function, exerts a
top-down control to enhance reward oriented behaviour
(Lesh et al., 2011; Levy and Dubois, 2006; Millan et al.,
2012). The abnormal activity of the DLPFC in schizophrenia
(Section 3.2) relates, then, in conjunction with impaired
executive function (coordination, planning, organisation),
to deﬁcits in the initiation and maintenance of goal-
directed, reward-seeking behaviour and its appropriate
linking to affect (Goghari et al., 2010; Kring and Barch,
2014; Millan et al., 2012; Strauss et al., 2013; Unschuld
et al., 2014; Ursu et al., 2011; Van Veelen et al., 2010).
The above observations collectively provide a framework
for conceptualising the amotivation and anticipatory anhe-
donia of NS not as a loss of hedonic state and reward
appreciation as such, but rather in terms of defective
cortico-striatal integrated processes indispensable for
reward acquisition and anticipatory pleasure. These deﬁcits
are interlinked with anomalies in emotional processing and
neurocognitive operations related to executive function and
episodic memory (recalling previous positive experiences
and prospective imaging of future pleasure), in line with the
involvement of other structures like the temporal lobe,
insular cortex, amygdala and hippocampal complex (Gradin
et al., 2011; Schacter et al., 2007; Millan et al., 2012; Ursu
et al., 2011).
In a nutshell, schizophrenic patients are unable to
assemble, get motivated by and exploit information about
previous pleasurable experiences in the service of goal-
directed and effort-requiring attainment of a future reward
(Burbridge and Barch, 2007; Deserno et al., 2013; Kring and
Barch, 2014; Strauss et al., 2014).3.4. Dysfunctional neural circuits related to
asociality
As regards a further sub-domain of NS, asociality, the
relevant structures disrupted in schizophrenia are less welldelineated than those underpinning anticipatory anhedonia,
and it is hard to tease them apart from those implicated in
impaired social cognition. Nonetheless, inasmuch as asoci-
ality is, at least partially, driven by a lack of (anticipatory)
social motivation, asociality presumably involves mechan-
isms and substrates outlined in the previous paragraphs.
Indeed, a role of the nucleus accumbens (striatum) in social
anhedonia has been evoked (Dowd and Barch, 2010).
Additional neural structures are also likely to be incrimi-
nated as deduced by studies in humans, by experimental
work in rodents and, in both cases, by studies of the “pro-
social” neuropeptide, oxytocin (Sections 3.6 and 4.8).
Thus, the disruption of an oxytocin-modulated network
incorporating the superior temporal gyrus, inferior frontal
gyrus, PFC and insula cortex, may contribute to social
withdrawal in schizophrenia (Churchland and Winkielman,
2012; Millan et al., 2012; Millan and Bales, 2013; Meyer-
Lindenberg et al., 2011). Further, oxytocin promotes social
behaviour and social motivation via actions in the nucleus
accumbens and amygdala (Dol̈en et al., 2013; Gordon et al.,
2011; Lee et al., 2005 Rosenfeld et al., 2011), and
anomalous cannibinoidergic signalling in these regions, in
interaction with the PFC, may also be involved in the loss of
sociality in schizophrenia (Seillier et al., 2010, 2013; Trezza
et al., 2011a, 2011b). These neurochemical observations,
further evoked below (Section 3.6), support a role for
anomalous operation of frontocortico-subcortical circuits
in the asociality of schizophrenia.
In addition, it might be speculated that a failure of the
default mode network to properly deactivate when switch-
ing from a self-referential to a social context, may con-
tribute to impaired social engagement in schizophrenia
(Bluhm et al., 2007; Broyd et al., 2009; Whitﬁeld-Gabrieli
and Ford, 2012; Mazza et al., 2013; Orliac et al., 2013).3.5. Dysfunctional neural circuits related to
diminished emotional expression
By analogy to asociality, information on the precise neural
substrates underlying diminished emotional expression also
remains fragmentary though loss of the expressive use of
non-verbal signals like hand gestures likely involves struc-
tures common to impaired social cognition (vide supra).
Furthermore, a complete dissociation of neural sub-
strates implicated in avolition compared to those involved
in blunted affect would seem improbable. In addition to
roles for the ventromedial PFC, DLPFC, anterior cingulate
and temporal cortex, impaired emotional processing and
expression in response to positive and negative emotional
stimuli may be related to anomalous activation of the
amygdala, and to changes in the dorsal striatum and
hippocampus/parahippocampal gyrus (Dowd and Barch,
2010; Kring and Elis, 2014; Fahim et al., 2005; Goghari
et al., 2010; Gur et al., 2007; Lepage et al., 2011; Rosenfeld
et al., 2011; Taylor et al., 2012; Ursu et al., 2011). A link
between dysfunctional language-speech networks incorpor-
ating the PFC, temporal, parietal and occipital cortices and
poor content of speech appears probable (Makris et al.,
2010; Millan et al., 2012; Poeppel, 2012), but the speciﬁc
neural foundations of alogia (decreased verbal ﬂuency) are
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Lepage, 2012; Potkin et al., 2002).
Finally, alterations in default mode activity and connec-
tivity of the ventromedial PFC and parietal cortex may be
linked to decreased verbal expression (Bluhm et al., 2007;
Orliac et al., 2013; Whitﬁeld-Gabrieli and Ford, 2012).
Further work remains to be undertaken to better deﬁne
the speciﬁc neural substrates implicated in the diminished
emotional expression of schizophrenia.
3.6. Onset of anomalies related to NS in at-risk
patients prior to diagnosis
To summarise, while many questions persist, anomalous
operation of a complex suite of partially-overlapping and
interacting cortico-subcortical circuits is implicated in the
various sub-domains of NS, and certain are common to
impaired social cognition. A broad role of the PFC in
interaction with the temporal cortex, striatum and amyg-
dala can be recognised, yet distinct sub-territories fulﬁl
differential roles, accounting for the contrasting functional
impact of their dysfunction. In addition, the signiﬁcance of
interacting regions like the insular and parietal cortices,
as well as the thalamus and cerebellum, should not be
neglected.
The earliest circuit irregularity antecedent to schizophre-
nia – assuming it exists – is not currently known, nor whether
it might act as a trigger for the complex pattern of
disruption related to NS. In this light, the increasing
application of imaging early in the disorder, during the
prodrome, and in young subjects with identiﬁed risk factors,
should progressively clarify the comparative time of emer-
gence of diverse neural anomalies linked to NS sub-domains.
Importantly, mirroring NS themselves, the underlying
structural, functional and electrophysiological changes are
manifest in at-risk and prodromal subjects and hence
anticipate the ﬁrst psychotic episode (Section 2.5). Notably,
even before diagnosis, grey matter volume reductions,
white matter changes and network disruption are seen in
structures like the PFC, temporal and insular cortices
(Fusar-Poli et al., 2012, 2013b; Smieskova et al., 2012),
together with perturbation of ERP depending upon fronto-
temporal-parietal circuits (Boutros et al., 2013; Kim et al.,
2014; Oribe et al., 2013; Ozgürdal et al., 2008). These
points are of signiﬁcance with respect to the development
of potential biomarkers for predicting transition of vulner-
able individuals to schizophrenia.
3.7. From neural substrates to cellular and
neurochemical bases of NS
Another important question – which bears on the chronology
of pathophysiological changes triggering NS – concerns
the molecular substrates of neural circuit dysfunction in
schizophrenia.
Various sub-domains of NS may be independently pro-
voked by contrasting cellular anomalies, such as aberrant
oxytocinergic transmission for asociality, or anomalous
cannabinoid/DA signalling for anticipatory anhedonia.
On the other hand, abnormal expression of proteins like
Reelin or Neuregulin-1 would impact a broad community ofGABAergic interneurons and cortical pyramidal neurones
dispersed across multiple regions of the PFC implicated in
NS: furthermore, the induction of an immune-inﬂammatory
response upon perinatal infection would likewise have a
widespread impact on the developing brain (Fatemi and
Folsom, 2009; Lewis, 2012; Millan, 2013; Moser, 2014;
Piontkewitz et al., 2012; Rapoport et al., 2012).
It remains then to be clariﬁed just how the various patterns
of neuronal and circuit dysfunction linked to sub-domains of
NS are interrelated in terms of their causes, interplay and
onset, and whether there exists a unifying and common
precipitating mechanism.
To determine the succession of events that ultimately
result in NS and schizophrenia itself, it will be necessary to
considerably improve our knowledge at the cellular level.
Compared to the rich pattern of data generated concerning
neural circuits, little is known at the neurotransmitter level
regarding NS since it is technically far more challenging to
undertake such studies on humans as compared to the
conventional imaging. Nevertheless, the following ﬁndings
– generally supported by experimental observations (Section
5) – justify mention.
Magnetic Resonance Spectroscopy data has provided
direct evidence that a disruption of GABA-glutamatergic
dialogue in the PFC and striatum is correlated with NS,
though a disequilibrium of the inhibitory-excitatory balance
is also related to neurocognitive and positive symptoms
(Poels et al., 2014; Reid et al., 2010; Rowland et al., 2013).
The endogenous antioxidant, glutathione, interacts with
NMDA receptors and may protect against the induction of
schizophrenia (Yao and Keshavan, 2011), so it is of note that
decreases in its levels correlate with the severity of NS
(Matsuzawa et al., 2008).
Positron Emission Tomography (PET) and SPECT permit
the characterisation of dopaminergic transmission in terms
of DA release and receptor occupation (Mugnaini et al.,
2013) and, as outlined by Kring and Barch (2014) and Barnes
et al. (2014), convergent clinical and preclinical evidence
support the core signiﬁcance of aberrant striatal and
prefrontal dopaminergic signalling in the motivational def-
icits of schizophrenia (Section 3.2). An interesting variant
on these data, and an approach that could be more widely
used to examine neurochemical substrates of NS, is pro-
vided by the ﬁnding that repetitive Transcranial Magnetic
Stimulation (TMS) of the PFC – which can relieve NS (Section
5.5) – elicits DA release in the human caudate (Stratella
et al., 2001). It should also be mentioned that a compara-
tively early deﬁcit in mesocortical dopaminergic transmis-
sion related to NS and cognitive impairment – itself
downstream of aberrant GABA-glutamate coupling – may
secondarily provoke the hyperactivity/hyper-responsiveness
of mesolimbic dopaminergic pathways manifested in posi-
tive symptoms at the time of the ﬁrst psychotic episode
(Lewis, 2012; Millan et al., 2012; Remington et al., 2011).
Especially intriguing are data pertaining to endogenous
cannabinoids in view of their role in reward mechanisms
expressed in the mesolimbic system in interaction with
dopamine (Der-Avakian and Markou, 2012; Leweke, 2012;
Leweke et al., 2012). Cerebrospinal ﬂuid levels of the
endogenous ligand, anandamide, are elevated in schizo-
phrenia. Similarly, the density of Cannibinoid (CB) 1 recep-
tors is higher in post-mortem tissue, and several studies
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the nucleus accumbens and PFC using highly-selective PET
ligands. Importantly, increases in CB1 receptor signalling in
the nucleus accumbens (and other structures) are nega-
tively correlated with NS. Accordingly, even though canna-
bis abuse is a risk factor for psychosis, it has been
speculated that endogenous cannibinoidergic mechanisms
play a counter-adaptive and protective role in the suppres-
sion of NS (Ceccarini et al., 2013; Coulston et al., 2011;
Leweke et al., 2012). This line of thinking will be of interest
to pursue.
Finally, to reiterate a point outlined above, decreased
oxytocinergic transmission appears to be implicated not
only in impaired social cognition but also in the genesis of
NS, including a loss of social motivation and interaction
(Churchland and Winkielman, 2012; Goodson and Thompson,
2010; Gordon et al., 2011; Meyer-Lindenberg et al., 2011).
That oxytocinergic signalling is defective in schizophrenia is
suggested by the modest correlation between reduced
cerebrospinal ﬂuid and plasma levels of oxytocin and the
magnitude of NS (Goodson and Thompson, 2010; Meyer-
Lindenberg et al., 2011; Rosenfeld et al., 2011; Rubin et al.,
2010; Sasayama et al., 2012). Though this relationship
would beneﬁt from conﬁrmation, a signiﬁcant associations
has been reported between Single Nucleotide Polymorph-
isms in the Oxytocin receptor gene and NS (Montag et al.,
2013). There is experimental evidence that an interaction
with serotonergic transmission in the nucleus accumbens
participates in the facilitation of social behaviour and
reward by oxytocin (Dol̈en et al., 2013), while oxytocin also
acts in the amygdala to favour social behaviour and
motivation (Gordon et al., 2011; Lee et al., 2005
Rosenfeld et al., 2011). Hence, deﬁcient oxytocinergic
transmission in these regions, and in cortico-subcortical
circuits underpinning social cognition and processing
(Section 3.3) (Meyer-Lindenberg et al., 2011). may be
related to the asociality of schizophrenia.
Other mechanisms potentially defective in schizophrenia
should also be brieﬂy evoked. These include mu-opioid
receptors which in the nucleus accumbens and in interac-
tion with DA, facilitate social and other mode of reward,
while kappa-opioid receptors act oppositely: further, like-
wise acting in this region, adenosine regulates reward-
related effort (Chartoff et al., 2012; Salamone et al.,
2012; Scholsburg et al., 2013; Trezza et al., 2011a, 2011b).3.8. Implications of insights into neural and
neurochemical substrates of NS for novel modes of
treatment
As summarised in the preceding section, our knowledge of
neurochemical substrates underpinning NS remains patchy,
and this restricted knowledge base continues to handicap
the elaboration of novel medication (Section 4). It is
difﬁcult to imagine that neuronal and (poorly understood)
glial mechanisms relevant to NS are limited to the handful
of examples evoked above – which themselves pose chal-
lenges for therapeutic utilisation, such as the contrasting
implication of dopamine (DA) D2 receptors in NS vs positive
symptoms, and the widespread and heterogeneous role of
glutamatergic transmission throughout the brain (Remingtonet al., 2011; Schobel et al., 2013; Poels et al., 2014).
Furthermore, it is not necessarily cellular processes impli-
cated in the genesis of NS that are the key issue – they may
be developmentally decoupled in time from treatment.
Rather, it is those processes involved in the maintenance
and counter-regulation of NS that best provide a potential
foundation for improved pharmacotherapy. The optimal
entrance point, as opposed to a susceptibility gene, would
be a modulatory mechanism (facilitatory or inhibitory)
upstream, downstream or in parallel to causal processes
and still accessible to manipulation. As an analogy, and
irrespective of whether 5-HT levels are genuinely deﬁcient
in major depression, SSRIs act by interfering with 5-HT
reuptake, yet a dysfunction of 5-HT transporters is not
incriminated in the aetiology of this disorder (Millan, 2006).
Concerning neural structures circuits related to NS, again
we have the problem of establishing their precise roles in
the maintenance and modulation of NS and, over and above
this, cerebral regions are not in themselves targets for
pharmacotherapy. Drugs acts at molecules, not on Brod-
mann areas. Nonetheless, such insights are instructive in
several ways. First, they provide potentially useful para-
meters for clinical development: either imaging biomarkers
for NS and patient stratiﬁcation, or surrogate measures of
medication efﬁcacy and target engagement during clinical
trials. Second, in the context of drug discovery, they suggest
which large-scale structures should best be modulated and
raise the possibility of the back-translation of imaging and
EEG ﬁndings into animal models for schizophrenia. EEG
procedures are pretty well characterised and, though still
challenging, progress is rapidly been made into structural
(white and grey matter) imaging in rodents, as well as fMRI
of neural activity – for example a default mode network has
recently been described (Bertrand et al., 2010; Broberg
et al., 2013; Chin et al., 2011; Dodero et al., 2013; Ellegood
et al., 2013; Schobel et al., 2013). This corresponds to the
“MATRICS” mantra of identifying comparable and transla-
table behavioural, electrophysiological and other readouts
across animals in order to facilitate drug discovery. Third,
cortical neural circuits can be directly recruited for the
relief of NS by stimulation strategies and, in a different
fashion, by cognitive-behavioural/psycho-social modes of
therapy likewise evoked below (Section 4.7).
4. Current and prospective therapy of
negative symptoms: clinical investigations
4.1. Studies of potentially improved treatment of
negative symptoms: general considerations
In view of their disabling nature and high prevalence, an
especially important topic addressed in this volume is the
current treatment of NS and prospects for improved control
(Arango et al., 2013;. Miyamoto et al., 2012). In this light,
the article by Davis et al. (2014) surveys the effects of
currently-available pharmacotherapy, and discusses on-
going clinical trials of potential new medication. The article
considers several complementary facets of the actions of
drugs for the management of NS including; methodological
issues and trial design – for which a consensus is emerging as
to how studies should best be performed (Marder and
M.J. Millan et al.660Kirkpatrick, 2014); efﬁcacy against primary compared to
secondary NS; and the actions of antipsychotics themselves,
antidepressants and diverse other classes of agent.
In this respect, it is worth pointing out that: (1) many
older monotherapy studies of antipsychotics were under-
taken with positive rather than NS as the primary readout,
and often in acute psychosis and (2) many recent studies of
“novel” mechanisms of action were designed for restoring
neurocognition in association with antipsychotics, with
measures of NS essentially “tagged on”, and the effects of
the drugs alone not always examined (Arango et al., 2013;
Davis et al., 2014; Hanson et al., 2010; Hartling et al., 2012;
Miyamoto et al., 2012; Murphy et al., 2006; Zhang et al.,
2013). Neither of these designs is optimal to detect an
impact of a drug (novel mechanism of action) against
primary NS. Indeed, clinical studies focussing on the inﬂu-
ence of monotherapy with innovative agents on primary NS
are still rare, but should become more frequent with: pro-
active Federal Drug and European Medicines Agency sup-
port, improved rating scales (Section 2.1) and agreement on
core criteria like the duration of trial (12 and 26 weeks for
Phase II and III respectively), exclusion of comorbid depres-
sion, and prior clinical stability for around 4–6 months
(Marder and Kirkpatrick, 2014).
The overview below has a very mechanistic “ﬂavour” in
highlighting the actions of selected interventions in relation
to their inﬂuence upon above-mentioned cerebral circuits
and neurotransmitters implicated in the pathogenesis
of NS, with a particular focus on: the PFC, dopaminergicTable 2 Overview of pharmacotherapeutic mechanisms for th
rodents.
2nd Generation
antipsychotic
(5-HT2A4D2)
Neuroleptic D3
antag.
5-HT2C
Negative
symptoms
0/+ 0/ + +
Impaired social
cognition
0/+/ 0/ ++ 0/+
Neurocognitive
symptoms
0/+/ 0/ +/++ 0/+
Positive
symptoms
++ + + + 0/
Other
beneﬁcial
properties
Low risk of EPS Marked EPS
provoke 21
NS
↓ Drug-
seeking
Anxioly
antidep
++, Robust activity; +, signiﬁcant activity; 0, no marked effect; –
patterns of data. The putative inﬂuence of mechanisms upon NS
potentially-useful actions are also indicated. The table is based m
generation antipsychotics like olanzapine, and neuroleptics like halo
upon NS is, as indicated, modest and variable: they robustly con
extrapyramidal syndrome, but no other obvious common beneﬁts
All speciﬁc mechanisms of action refer to receptors. Although feed
symptoms uncertain, D3 antagonists appear of especial interest.
facilitator, they have yielded a mixed bag of data in patients and ro
may be more effective, but this remains to be demonstrated. F
documented and await consolidation. GABA A receptor facilitation p
explore additional mechanisms for potentially improving the control o
cannibinoidergic modulators and the anti-inﬂammatory agent, minocy
Abbreviation not in text: EPS, Extrapyramidal syndrome.transmission, N-Methyl-D-Aspartate (NMDA) receptors,
GABAergic signalling, oxytocin and serotonin. The proﬁles
of three instructive agents are highlighted in view of the
attention that have attracted (and that they are still
attracting), albeit for very different reasons: amisulpride,
bitopertin and oxytocin. In addition, in light of the current
inadequacies of pharmacotherapy, quite extensive consid-
eration is devoted to “alternative” stimulation-based and
cognitive–behavioural–psychosocial approaches which have
yielded promising data and appear to act via the modulation
of cortico-subcortical networks underlying NS.4.2. Limited efﬁcacy of established and recently-
introduced antipsychotics for controlling NS
4.2.1. Neuroleptics and second generation
(5-HT2A4D2) antipsychotics
Despite their efﬁcacy against positive symptoms in the
majority of subjects, and mirroring their limited relief of
impaired social cognition and neurocognitive deﬁcits, NS are
poorly controlled by currently-available medication such as
haloperidol, and second-generation successors like olanza-
pine and risperidone (Table 2) (Citrome, 2013; Hartling
et al., 2012; Leucht et al., 2013; Naber and Lambert,
2009; Zhang et al., 2013). Further, induction of extrapyr-
amidal symptoms at higher doses of neuroleptics risks the
induction of secondary NS, though this happens only rarely
these days (Remington et al., 2011). It was comparisons toe potential control of NS as based on pre-clinical studies in
antag. 5-HT7 antag. NMDA
facilitator
GABA A
facilitator
Oxytocin
facilitator
+ + + ++
0 + 0/+ ++
0/+ +/++ + 0
0 + + 0/+
tic
ressant
Antidepressant ↓
Conditioned
fear
Anxiolytic ↓ Social
anxiety
potentially deleterious impact. 0/+, 0/ and 0/+/, Variable
is indicated in relation to other cardinal symptoms, and other
ainly on ﬁndings in rodents, with the exceptions of second-
peridol. The clinical impact of second-generation antipsychotics
trol positive symptom in most patients and do not provoke a
have yet been identiﬁed in the treatment of schizophrenia.
back from patients is awaited, and putative control of positive
As regards mechanistically-diverse classes of NMDA receptor
dents: potentiation of endogenous D-Serine rather than Glycine
or oxytocin receptors, promising therapeutic data have been
rincipally refers to the α2 subtype. There is an urgent need to
f NS: in this respect, intriguing data have been reported for both
cline. See text and Davis et al. (in press) for further information.
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provoke an extrapyramidal syndrome that initially implied
the advantage of clozapine for alleviating NS, but more
recent and longer-term investigations, studies in compar-
ison to antipsychotics with a lesser propensity to induce NS,
and observations in patients displaying predominant NS
suggest that it is principally effective against secondary
NS, and that its ostensible effectiveness against primary NS
possibly reﬂects superior control of positive symptoms
(Citrome, 2013; Davis et al., 2014; Hartling et al., 2012;
Leucht et al., 2013). For second-generation antipsychotics,
there is only inconsistent evidence for advantages vs older
agents in terms of efﬁcacy against NS (Leucht et al., 2013;
Hartling et al., 2012; Naber and Lambert, 2009; Zhang
et al., 2013). This does not, at least in one sense, seem so
surprising. Notwithstanding a potpourri of pharmacological
activities, these agents are typiﬁed by their common and
preferential 5-HT2A over D2 receptor antagonist proﬁles
which, while diminishing the risk of an extrapyramidal
syndrome – and perhaps effective for moderating hallucina-
tions – would not, on a mechanistic basis, be anticipated to
markedly reinforce the control of NS (Citrome, 2013;
Meltzer, 2012; Miyamoto et al., 2012; Millan et al., 2000).4.2.2. A role for α2-adrenoceptor blockade in
antipsychotic impact on NS
Some recently-introduced agents have been oriented
towards the improved control of NS on the grounds of more
relevant pharmacological properties. For example, block-
ade of α2-adrenoceptors reinforces frontocortical vs meso-
limbic DA release and may, in theory, exert a beneﬁcial
inﬂuence upon certain sub-domains of NS (Brosda et al.,
2014; Franberg et al., 2012; Millan et al., 2000, 2012).
Asenapine shows high antagonist potency at α2-
adrenoceptors compared to other second-generation agents
(Franberg et al., 2012), and also behaves as a 5-HT1A and 5-
HT6 receptor antagonist which should favour cognitive
performance (Loiseau et al., 2008; Meffre et al., 2012;
Millan et al., 2012). Indeed, reports of beneﬁcial effects of
sublingual asenapine against NS (Weber and McCormack,
2009; Citrome, 2013) are intriguing and over 52 – but not 26
– weeks it out-performed olanzapine. Nonetheless, it has
not been authorised for control of NS and, unless under-
pinned by more robust ﬁndings, putative control of NS by
asenapine seems unlikely to be of major relevance in a
routine context (Arango et al., 2013; Buchanan et al., 2012;
Citrome, 2013; Potkin et al., 2013). Moreover, the contribu-
tion of α2-adrenergic receptor blockade to its actions
remains to be elucidated and several other antipsychotics
similarly elevate frontocortical release of DA by contrasting
mechanisms: 5-HT1A partial agonism (ziprasidone) and 5-
HT2C receptor blockade (olanzapine). As for clozapine,
relative to modest D2 receptor blockade, it possesses all
three of these actions and robustly increases dialysis levels
of DA in the rodent PFC (Meltzer, 2012; Millan et al., 2000).
Thus, it is uncertain how the molecular signature of
asenapine relates to any distinctive inﬂuence on NS, and
to what extent increases in frontocortical release of DA may
be related to its putative relief of NS (see Section 4.3 for a
further consideration of the role of DA release in the PFC).4.2.3. Case report: amisulpride and the potential
signiﬁcance of 5-HT7 receptor blockade
The benzamide derivative, amisulpride, also warrants a
brief digression for several reasons, some of them para-
doxical.
First, it is authorised for treating NS in several countries
(including France, its homeland), despite the fact and the
overall clinical picture for efﬁcacy still remains rather
nebulous. Early studies uniformly suggested improvement
of NS, yet with ambivalent efﬁcacy against positive symp-
toms, while other studies questioned its superiority to
olanzapine and haloperidol at equi-effective doses vs posi-
tive symptoms (Leucht, 2004; Mol̈ler, 2003). More recent
work remains ambiguous concerning any putative and
speciﬁc impact upon primary NS (Ahn et al., 2011; Leucht
et al., 2013; Nuss and Tessier, 2010; Zhang et al. 2013).
Second, reﬂecting its unusually poor blood brain barrier
penetration, despite potent (low nM) afﬁnity at D2/D3 recep-
tors, amisulpride has a long onset of action and necessitates
administration of very high doses of up to 500–1000 mg. It was
proposed that doses at the lower end of this range (50–300) are
most appropriate to controlling NS since they preferentially
occupy extra-striatal D2 receptors whereas higher doses (400–
1200) are more suitable for moderating positive symptoms in
that they block striato-accumbus populations of D2 receptor
(Bressan et al., 2003; La Fougère et al., 2005; Meisenzahl et al.,
2008; Mol̈ler, 2003). However, there is no obvious reason why
the former mechanism should counter NS, proposed explana-
tions of preferential D3 vs D2 receptor blockade and/or
antagonism of pre vs postsynaptic D2 receptors have little real
foundation, and amisulpride does indeed occupy striatal popu-
lations of D2 receptor at clinically-active doses (La Fougère
et al., 2005; Meisenzahl et al., 2008). Thus, the putative
efﬁcacy of amisulpride against NS would appear to require an
alternative hypothesis.
Third, while amisulpride can be distinguished from the
prototypical preferential 5-HT2A4D2 receptor proﬁle of other
second generation antipsychotics, recent studies have shown
that it is not entirely “devoid of serotonergic actions” in that it
possesses signiﬁcant antagonist properties at 5-HT7 receptors.
Though other agents like olanzapine also recognise these sites,
their 5-HT7 actions are swamped by their additional receptor
interactions at muscarinic receptors, histamine H1 receptors
and α1-adrenoceptors etc. (Citrome, 2013). By contrast, the
more discrete antagonism of 5-HT7 receptors may be impli-
cated in the actions of amisulpride in animal models related to
NS (Abbas et al., 2009; Nikiforuk et al., 2013). Moreover,
antagonism of 5-HT7 receptors is associated with antidepres-
sant properties in rodents (Hedlund, 2009), which have also
been reported for amisulpride (Abbas et al., 2009). This is of
particular relevance since its apparent relief of NS may be
secondary to a reduction of depressed mood (Buchanan, 2007).
Further evaluation of the signiﬁcance of 5-HT7 receptor
blockade to the control of NS may be warranted.4.3. Antidepressants and reinforcement of
frontocortical dopaminergic transmission: a role for
5-HT2C receptor inactivation?
As mentioned above, compromised activity of mesocortical
dopaminergic pathways has been implicated in NS, though it
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all classes of clinically-active antidepressant increase extra-
cellular levels of DA in the FCX in freely-moving rodents via
a variety of mechanisms, including (1) blockade of 5-HTC
receptors and α2-adrenoceptors (mirtazepine) and (2) indir-
ect recruitment of 5-HT1A autoreceptors (5-HT reuptake
inhibitors like citalopram) (Alex and Pehek, 2007; Brosda
et al., 2014; Meltzer, 2012; Millan, 2006). The beneﬁcial
inﬂuence of antidepressants upon social anxiety via 5-HT2C
receptor blockade or 5-HT2C receptor desensitization
(uptake inhibitors) (Dekeyne et al., 2000; Millan, 2006),
and the possibility that relief of depressed mood may
secondarily improve NS, has encouraged studies of the co-
administration of antidepressants with antipsychotics
(Hanson et al., 2010; Davis et al., 2014).
In fact, the latter point remains the crux of the issue
since, despite modest evidence that augmentation with
antidepressants like mirtazapine and citalopram may be
favourable in patients with prominent NS, effects are
modest and it is uncertain whether NS are directly impacted
or indirectly improved via alleviation of depressed mood
(Arango et al., 2013; Davis et al., 2014; Kishi and Iwata,
2013; Rummel et al., 2006; Singh et al., 2010; Sommer
et al., 2012). It also remains unclear whether the potentia-
tion of frontocortical DA release is fundamental to their
actions, since most second generation antipsychotics like-
wise promote DA release in the PFC of rodents, despite
inactivity against NS (Meltzer, 2012). Another potential
mechanism of antidepressant action would be strengthening
of reward mechanisms by an as yet poorly-understood
enhancement (not requiring DA release) of postsynaptic
DA signalling in the nucleus accumbens – though it is unclear
why this action would not exacerbate psychosis (Millan,
2006; Remington et al., 2011). Adrenergic and serotonergic
actions mediated independently of DA transmission and
affecting reward, motivation and social behaviour may
likewise be implicated in the actions of antidepressants
(Millan, 2006). These issues lie beyond the remit of this
paper yet, irrespective of mechanistic and conceptual
deliberations, an agent that both alleviates depressed
affect and NS would be attractive to patients, so further
study of the clinical impact and mechanisms of action of
antidepressants against NS appears desirable (Chertkow
et al., 2009; Kishi and Iwata, 2013).
It is possible that induction of frontocortical DA release is
related to the actions of other classes of adjunctive agent
under evaluation in schizophrenia such as nicotinic α7
modulators, though greater interest has been ascribed to
their putative improvement of cognition rather than NS
(Jones et al., 2012; Millan et al., 2012), an issue considered
by Davis et al. (2014) in this volume.
These authors likewise discuss adjunctive use of the
vigilance-promoting agent, modaﬁnil, as well as the psy-
chostimulants, methylphenidate and lis-dexamphetamine,
for the treatment of NS inpatients stabilised on antipsycho-
tics. However, their genuine efﬁcacy at acceptable doses
not risking exacerbation of psychosis remains an issue.
In addition, it is unclear to what extent the increase in
frontocortical DA and noradrenaline levels (related to
enhanced attention) are involved in their putative actions
compared to actions on limbic-striatal pools of DA (favouring
motivation and reward (Lindenmayer et al., 2013; Remingtonet al., 2011)). Other mechanisms should not be excluded for
modaﬁnil, a particularly promiscuous agent (Millan, 2006;
Scoriels et al. 2013).
Overall, there are arguments that strengthening compro-
mised mesocortical DA transmission in schizophrenia might
favourably inﬂuence NS, but rigorous proof is lacking, no
agent has yet been described that speciﬁcally recruits this
mechanism to alleviate NS, and this is unlikely to be
sufﬁcient alone as exempliﬁed by second-generation anti-
psychotics which enhance DA release in the PFC of rodents
yet fail to robustly control NS. Note, moreover, that
Phencyclidine (PCP) markedly accelerates the release of
DA in the PFC of rodents (Millan et al., 1999), yet it is hardly
an efﬁcacious treatment for NS! Interestingly, there appears
to be a bell-shaped relationship for DA release in the PFC
and function either insufﬁcient or excessive frontocortical
dopaminergic transmission is deleterious to affect, cogni-
tion and behaviour, and hence might be linked to NS (Balla
et al., 2012; Millan et al., 1999; 2012; Remington et al.,
2011).
Finally, it is possible that mechanisms independent of
monoamines are involved in the actions of antidepressants,
such as interactions with sigma1 receptors and ion channels
(Millan, 2006) or, as recently proposed, modulation of
GABAA receptor-mediated signalling (Silver et al., 2011).4.4. Anxiolytics and positive modulation of GABAA
receptors
As recently reviewed elsewhere (Dold et al., 2013), though
possibly useful for short term control of agitation and
aggression (Gillies et al., 2013), there is little evidence
for the utility of adjunctive benzodiazepines in the manage-
ment of NS. Despite the not unreasonable argument that
relief of social anxiety might secondarily diminish NS, this
remains to be demonstrated. Benzodiazepines act as posi-
tive allosteric modulators (PAMs) at GABAA receptors, which
retain their interest in light of the functional down-
regulation of frontocortical chandelier GABAergic interneur-
ones in schizophrenia. More speciﬁcally, loss of GABAα2
subunit on pyramidal neurone axon initial segments may
contribute to the desynchronisation of frontocortico-
subcortical glutamatergic circuits (Hines et al., 2013;
Lewis, 2012; Stan and Lewis, 2012). Interestingly, a recent
fMRI study related alterations in GABAA signalling in the PFC
to the modulation of affect, and actions of lorazepam were
more pronounced in schizophrenic patients, perhaps reﬂect-
ing loss of GABAergic inhibition and GABAA receptor super-
sensitivity (Taylor et al., 2014). While the GABAAα2 agonist,
MK 0777, exerted little beneﬁt on cognitive symptoms in
association with antipsychotics (Buchanan et al., 2011a), it
would be interesting to evaluate its actions as monotherapy
in patients with predominant NS, and as early as possible in
the disorder (Lewis, 2012; Millan et al., 2012).
Interest in GABAA receptor modulation is supported by
observations with the neurosteroid, pregnenolone, of which
the metabolite allopregnenolone behaves as a PAM at
GABAA receptors. Both experimental and clinical data
suggest that adjunctive pregnenolone alleviates NS (and
possibly cognitive symptoms). While its precise mechanism
of action awaits clariﬁcation and clinical data require
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further study (Kreinin et al., 2014; Ritsner et al., 2010,
2014; Marx et al., 2011) supported by studies in animals
(Wong et al., 2012).
4.5. Correcting anomalous glutamatergic
transmission: metabotropic and ionotropic (NMDA)
receptors
4.5.1. Positive modulation of Glycine B sites on NMDA
receptors
In fact, there is evidence that pregnanolone itself potenti-
ates transmission at NMDA receptors (Marx et al., 2011).
This is of relevance since one well-established hypothesis in
schizophrenia is that a hypoactivity of frontocortical NMDA
receptors results in reduced activity of chandelier GABAer-
gic interneurons, leading in turn to the above-mentioned
disorganisation of neural networks linking cortical and sub-
cortical structures (Coyle et al., 2012; Gilmour et al., 2012;
Millan, 2005; Stan and Lewis, 2012).
Accordingly, one argument underlying the development
of metabotropic glutamate 2/3 partial agonists/PAMs for
schizophrenia was that, by virtue of their actions at
metabotropic glutamate 2 autoreceptors on glutamatergic
neurones, they would “normalise” the activity of disinhib-
ited glutatamatergic pathways, as shown by their blunting
of PCP-induced glutamate release in the FCX of rats.
Nevertheless, despite promising initial data for both NS
and positive symptoms, further clinical studies proved
inconclusive (Hashimoto et al., 2013; Stauffer et al., 2013).
A direct approach to restituting the activity of NMDA
receptors surmised to be deﬁcient in schizophrenia is to
recruit their positive, modulatory Glycine B site (De
Bartolomeis et al., 2012; Hashimoto et al., 2013; Javitt,
2012; Millan, 2005). Though no Glycine B drug has ever been
tested alone, an extensive series of small scale and larger,
controlled multi-centre clinical studies has been undertaken
with: (1) the endogenous agonists, Glycine and D-Serine,
(2) the synthetic partial agonist, D-Cycloserine and (3) the
endogenous inhibitor of glycine reuptake, sarcosine, in
association with antipsychotics other than clozapine – which
itself reinforces NMDA transmission, thereby compromising
study outcome (Millan, 2005). Brieﬂy summarised, these
studies have yielded a chequered pattern of data permitting
no deﬁnitive conclusions (nor, of course, drug authorisations)
yet with the most promising suggestion of efﬁcacy – some-
what counter-intuitively – for NS rather than for cognitive or
positive symptoms, and with greater activity associated with
full rather than partial agonism, exerted either directly or
via suppression of glycine reuptake (Buchanan, 2007; De
Bartolomeis et al., 2012; Gilmour et al., 2012; Javitt, 2012;
Kantrowitz and Javitt, 2010; Lane et al., 2010; Singh and
Singh, 2011; Weiser et al., 2012).
4.5.2. Case report: the Glycine 1 transporter inhibitor,
bitopertin – hot off the press
These clinical observations and the above-evoked notion that
NMDA receptor hypoactivity may be pivotal to the aetiology
of schizophrenia, prompted the development of bitopertin,
a highly selective ligand at Glycine 1 transporters, which are
localised in the vicinity of neurones bearing NMDA receptorsin the PFC and other cerebral regions (Alberati et al., 2012).
Guided by PET studies of target engagement, a double-blind,
placebo-controlled, 8 week randomised study of subjects
with predominantly NS revealed signiﬁcant effects of 10 and
30 mg in the NS factor score of the PANSS and in Clinical
Global Improvement, whereas a higher dose of 60 (mirroring
the “inverted U” dose-response of direct ligands (De
Bartolomeis et al., 2012)) did not separate from placebo
(Umbricht et al., 2010).
The promising – though not overwhelming – Phase II data,
coupled to an excellent safety proﬁle, encouraged the
decision to simultaneously launch three Phase III add-on
trials in patients with persistent and predominant NS. Three
further and large add-on trials with doses of 5–20 mg of
bitoperin were also initiated in patients with suboptimal
control of all symptoms, likewise over 52 weeks, and in the
same centres. The primary endpoint of the three NS trials
was the PANSS at 24 weeks.
Frustratingly, Roche have just revealed that the initial
outcome of the bitopertin studies for persistent and pre-
dominant NS was negative. No other details nor analyses are
as yet available, but it is important to consider why these
studies may not have succeeded overall in view of: their
considerable interest; the inevitable fall-out; and potential
insights into putatively responsive patient sub-groups and
related therapeutic strategies.4.5.3. From FCX pools of Glycine to D-Serine for
improved control of NS
It may be that use of newer NS metrics mentioned above
(Section 2.) would have been more successful – and sensitive
– and a focus on NS sub-clusters might also have been more
insightful. As regards mechanistic explanations, stress-
induced glutamate release in hippocampus is implicated in
the induction of psychotic states, so actions at NMDA
receptors in this region may be deleterious (Schobel
et al., 2013). In addition, we have little idea of how
facilitating NMDA activity in other subcortical structures
implicated in the genesis and putative control of NS, like
the dorsal striatum, nucleus accumbens and amygdala, may
affect their expression. A further issue is the preferential
localisation of Glycine 1 transporters in hindbrain vs fore-
brain stuctures, where they more markedly elevate extra-
cellular levels of glycine than in the PFC itself (Gobert
et al., 2011 and pers.comm.). Perhaps most fundamentally,
however, following initiation of the bitopertin studies,
evidence emerged that D-Serine rather than glycine may
be the principle endogenous ligand gating NMDA receptors
controlling synaptic plasticity in PFC (Papouin et al., 2012;
Fossat et al., 2012). Though such observations are most
obviously related to the control of cognition, they are
ultimately also germane to NS.
Thus, apart from the all too familiar message that a
positive Phase II outcome is no guarantee of Phase III
success, there may be something of a silver lining. Rather
than fruitlessly searching for other ligands that putatively
increase levels of endogenous Glycine at NMDA receptors in
PFC, greater success may be acquired with strategies that
preferentially elevate extracellular levels of D-Serine.
A “bitopertin-mimic” strategy aimed at increasing ambient
levels of D-Serine will depend upon further characterisation
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(Hashimoto et al., 2013; Millan, 2005; Sacchi et al., 2013).
Alternatively, D-Serine signalling may be strengthened by
inhibition of the degrading enzyme, D-Amino-acid-Oxidase
(Ferraris and Tsukamoto, 2011). Indeed, very recently, the
D-Amino-acid-Oxidase inhibitor, benzoate, was found to be
effective in both PANSS total and NS sub-scale scores in a
6 week, double-blind, placebo-controlled add-on trial of
chronic schizophrenia (Lane et al., 2013). Clearly, conﬁrma-
tion of these encouraging data in more extensive trials of
longer duration, and employing more selective inhibitors,
would be desirable.
A further strategy would be to inhibit the synthesis of
kynenurenic acid, an endogenous antagonist of the Glycine
B sites which likewise behaves as an antagonist of nicotinic
α7 receptors, suggesting a double therapeutic advantage for
controlling NS – and neurocognitive impairment (Alexander
et al., 2012; Jones et al., 2012; Schwarcz et al., 2012).4.6. Recruitment of cortical networks by
stimulation techniques
The traditional notion of hypofrontality per se as a causal
factor underlying NS and other non-positive facets of
schizophrenia has been superseded by a more sophisticated
and reﬁned model of state, sub-territory and time-
dependent dysfunction expressed in interaction with corti-
cal and sub-cortical networks (Section 3.2). Anomalous
operation of the PFC, including hypoactive NMDA receptors,
down-regulated GABAergic interneurones, desynchronised
pyramidal neurones and blunted DA release are nonetheless
implicated in the pathophysiology of schizophrenia, includ-
ing NS (see above). Not least owing to the long kinetics of
new drug development, and limited progress to date with
new classes of agents, there is increasing interest in other
strategies for modulating the action of the PFC and further
cortical regions to therapeutic ends.
High frequency (410 Hz) rTMS of the PFC, in particular the
DLPFC, enhances brain metabolism and excitability. It has
been reported (in several though not all studies) to be
effective in the relief of NS when applied for several weeks
early in the course of schizophrenia, with an impact on several
subdomains of NS (except alogia), and independent of any
change in depressive symptoms (Barr et al., 2012; Prikryl
et al., 2013; Prikryl and Kucerova, 2013; Shi et al., 2014).
Interestingly, there is some evidence that its actions involve
modulation of NDMA receptors and striatal DA release, possibly
to favour motivation (Pell et al., 2011; Stratella et al., 2001).
Transcranial, direct current stimulation involves the
application of a weak electric current via two electrodes
to increase neuronal excitation in the underlying regions of
the brain. Despite some conﬂicting observations, it holds
promise for the monotherapy of major depression (Berlim
et al., 2013), can promote social cognition (when applied
over the temporo-parietal junction) (Santiesteban et al.,
2012), and is currently under study for the treatment of NS
(and auditory hallucinations) of schizophrenia. Electrodes
are placed over the left DLPFC (anode) and temporopartie-
tal junction (cathode), and recruitment of cortico-
subcortical networks appear to be involved in its beneﬁcial
impact on NS, though this awaits conﬁrmation and theeffects of direct current stimulation depend, like those of
rTMS, upon the precise parameters of stimulation employed
(Agarwal et al., 2013; Brunelin et al., 2012).
Ongoing studies should help standardise stimulation para-
meters and clarify the genuine utility of these approaches
for recruitment of frontocortical mechanisms and the
alleviation of NS.4.7. Cognitive and psychosocial interventions for
relieving NS: implication of frontocortical circuits
A different approach to restore the functionality of cortico-
subcortical circuits disrupted in schizophrenia consists in
the application of interrelated – and sometimes combined –
“cognitive-behavioural-psychosocial” therapies. A diverse
palette has been described, certain of which are proposed
for the treatment of NS and/or impaired neurocognition and
deﬁcits in social cognition. They are undertaken either
individually or as group therapy, and almost invariably on
top of antipsychotic medication to guarantee robust control
of positive symptoms (Barsaglini et al., 2014; Elis et al.,
2013; Johnson et al., 2013; Valencia et al., 2013).
The behavioural training (practise) technique of Cognitive
Remediation Therapy (CRT) aims to endurably rekindle key
skills related to neurocognition and social cognition, and has
been shown to recruit a distributed network of frontocortical
structures including the inferior frontal gyrus, DLPFC and
anterior cingulate cortex, all implicated in NS (Section 3.2)
(Bor et al., 2011; Haut et al., 2010; Wykes et al., 2011). The
(modest) amelioration of NS by tailored programmes of CRT
includes an decrease in avolition and may be related to an
enhancement of motivation (Elis et al., 2013; Klingberg et al.,
2012; Sanchez et al., 2014; Wykes et al., 2011). Though
enhanced executive function may help improve patient out-
come following CRT, its contribution remains unclear.
A rather different approach is represented by Cognitive
Behavioural (or simply Cognitive) Therapy (CBT) – the ﬁrst
“alternative” mode of therapy to be formally endorsed by
national organisations both in the UK and US (Buchanan
et al., 2010; Dixon et al., 2010, Jauhar et al., 2014). This
technique more speciﬁcally targets poor motivation and
anhedonia together with negative and defeatist beliefs, and
promotes the active engagement of patients to attain
deﬁned goals: it can be oriented to an individual's strengths
and has as a core objective improved functional status and,
if possible, recovery (Beck et al., 2013; Grant et al., 2012).
Several papers have reported a positive though moderate
impact of CBT on NS (mainly in association with antipsycho-
tics), with a reduction of apathy and enhanced motivation,
including studies in patients with predominant NS. Beneﬁts
depend upon the conditions of application, individual ses-
sions are more effective than group therapy, not all studies
have been successful and overall effect size is modest for NS
– and positive symptoms (Elis et al., 2013; Jauhar et al.,
2014; Morrison et al., 2014). Also, just how speciﬁc and
marked the impact of CBT on NS is compared with CRT
remains to be clariﬁed (Klingberg et al., 2012). Nonethe-
less, in light of evidence for enduring post-treatment
efﬁcacy in major depression, where it has been more
extensively studied, it is interesting that effects may
persist after discontinuation in schizophrenia – though this
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permanent cure (Cuijpers et al., 2013; Elis et al., 2013;
Grant et al., 2012; Hollon et al., 2006; Sarin et al., 2011).
Underpinning the signiﬁcance of higher level operations in
the mediation of CBT, there is evidence for a role of
functional changes in the striatum and other cerebral
regions like the insular cortex in transducing its effects on
emotional processing, though the relationship of such
changes to NS awaits clariﬁcation (Kumari et al., 2011).
A ﬁnal and complementary intervention worth highlighting
here is Social Skills Training which aims to moderate NS by the
use of intensive and structured modules that educate patients
about skills needed to improve their social function in the
community, including reciprocal use of verbal and nonverbal
exchanges. A reinforcement of social cognition is evidently an
important element of this approach for countering NS, under-
scoring arguments made above concerning their close inter-
relationship and underpinning the notion that NS lie at least
partially downstream of social cognition/processing (Section
2.3) (Figure 4) (Elis et al., 2013; Valencia et al., 2013). Evidence
is accumulating to suggest the utility of group Social Skills
Training for relief of NS (Elis et al., 2013; Rus-Calafell et al.,
2013). Interestingly, coupled to family psychoeducation, Social
Skills Training was a lynchpin of the broad-based early-inter-
vention “OPUS” programme in Denmark which reported positive
ﬁndings for the improvement of NS in individuals with ﬁrst-
episode psychosis (Hastrup et al., 2013; Nordentoft et al.,
2014).
As for CRT and CBT, standardisation is an issue with Social
Skills Training, and it remains to be determined just how
general, robust, broadly-applicable and cost/time-effective
each of these interventions would be when used on a larger
scale outside the framework of controlled and specialist-
coordinated trials, but cautious optimism seems warranted
(Jauhar et al., 2014). Further, by analogy to the uniting of
pharmacotherapy and non-drug based strategies, combining
cognitive-behavioural-psychosocial therapies could poten-
tially boost efﬁcacy, as reﬂected by Integrated Psychologi-
cal Therapy, though no rigorous comparative data are yet
available (Elis et al., 2013; Roder et al., 2011). Intriguingly,
“cognitive-behavioural-psychosocial” therapies appears to
improve the real-world function of patients, and vocational
reintegration itself moderates NS, implying a sort of
“positive feedback” (Bio and Gattaz, 2011).
As a ﬁnal remark, while the focus above was on the PFC,
certain alternative therapies like Social Skills Training likely
facilitate social communication and motivation by promot-
ing oxytocin release, itself deﬁcient in NS. Yoga has been
claimed as useful for treating NS and, notwithstanding any
reservations concerning the rigour of the underlying studies,
yoga therapy aimed at improving socio-occupational func-
tion was reported to increase plasma oxytocin levels
(Jayaram et al., 2013). Thus, we may conclude this over-
view of potential routes to superior therapy of NS with a
brief consideration of the use of this hormone itself.4.8. Oxytocin: countering NS via reinforcement
of social cognition/processing
As pointed out above (Section 2.3), the interface between NS
and impaired social cognition-processing is somewhat blurredwith several communalities in terms of their expression,
underlying causes and neural substrates. It might be argued
that certain domains of NS lie at least partially downstream of
– and are driven by – impairments in social cognition as regards
both of its components, emotional processing and Theory of
Mind. Hence, reinforcing social cognitive should have a
beneﬁcial inﬂuence upon NS. While the pharmacology of social
cognition is not well developed, based on both experimental
and clinical work, at least one critical modulator has been
identiﬁed, oxytocin. This neuropeptide possesses its own class
of centrally localised oxytocin receptor, and interacts with a
variety of neuromodulators in the expression of its actions,
including 5-HT and DA in the nucleus accumbens and amyg-
dala, respectively (Goodson and Thompson, 2010; Meyer-
Lindenberg et al., 2011; Millan and Bales, 2013; Millan
et al., 2012; Rosenfeld et al., 2011).
As discussed elsewhere, though its long-term actions
appears to be rather more complex and less unitary than
originally thought (De Berardis et al., 2013; Huang et al.,
2014; Modabbernia et al., 2013), oxytocin is a powerful
facilitator of social cognition under a diversity of conditions.
By analogy to autism, intra-nasal administration of oxytocin
favours at least some components of social cognition in
schizophrenia, notably Theory of Mind and emotion recogni-
tion (Davis et al., 2013; De Berardis et al., 2013; Fischer-
Shoffy et al., 2013; Millan et al., 2012). Further, certain
studies suggest a beneﬁcial impact of adjunctive, long term
(several weeks) – but not single dose (Davis et al., 2013) –
administration of intranasal oxytocin on NS in patients
stabilized on antipsychotics (Feifel et al., 2010; P.R. Lee
et al., 2013; Modabbernia et al., 2013; Pedersen et al.,
2011). These studies require consolidation and it is unclear:
exactly which populations of patients are most likely to
respond; in what context (possibly social enrichment); and
as concerns which dimensions of NS – though avolition and
anhedonia have been proposed (P.R. Lee et al., 2013). It
also remains to be established via which neuronal substrates
oxytocin exerts its actions. Animal studies suggest a role
for: (1) the nucleus accumbens in interaction with reward
mechanisms and 5-HT (Dol̈en et al., 2013) and (2) the
amygdala-PFC in interaction with dopamine and emotional
processing (Rosenfeld et al., 2011), though these networks
are likely interrelated. Oxytocin may also counter NS by
promoting social motivation (Gordon et al., 2011), or via a
more strictly social cognitive mechanism such as an
enhancement of Theory of Mind (Section 3.6) (Churchland
and Winkielman, 2012; Davis et al., 2013; Millan et al.,
2012; Pedersen et al., 2011).
To echo a comment made above, irrespective of mechanistic
niceties, a dual improvement in social cognition and NS would
be particularly appealing for restoring function both in schizo-
phrenic subjects and in at-risk individuals prior to diagnosis.
This promising avenue of research will hopefully soon be
consolidated and accelerated by the clinical availability of
non-peptidergic PAMs at oxytocin receptors (Ring, 2010).4.9. Prospects for improved clinical evaluation
and treatment of NS
As evoked above, a common feature of pharmacotherapeu-
tic, stimulation and cognitive–behavioural–psychosocial
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anisms integrated in cortico-subcortical circuits, especially
those involving the PFC. However, the precise neurochem-
ical pathways engaged remain to be further clariﬁed and
they presumably differ amongst various clinical strategies,
each of which acts via a multiplicity of neural substrates.
It should also be stressed that, despite encouraging
results, no medication or alternative approach under inves-
tigation promises to become a panacea in terms of universal
and robust efﬁcacy, cost effectiveness, ease of application,
use as monotherapy and long-term control of NS together
with other classes of symptom. Despite all this, there are
grounds for guarded optimism.
First, from a methological perspective, there is an emer-
ging consensus as to how focussed clinical trials should be
optimised for revealing a potentially beneﬁcial inﬂuence of
a novel candidate drug against primary NS: inclusion
criteria, length of treatment and many other variables are
becoming increasingly well deﬁned to favour the likelihood
of a successful outcome (Marder and Kirkpatrick, 2014).
In addition, the European Medicine and Federal Drug
Agencies appear increasingly open to dialogue concerning
innovative trial designs and novel concepts for treating
NS and other unmet needs in schizophrenia. Furthermore,
several novel rating scales under exploration appear to
be more reliable and sensitive than conventional tools for
monitoring the beneﬁts of therapy (Section 2.1) (Malaspina
et al., 2014; Marder and Kirkpatrick, 2014). Within this
framework, it should soon become possible to differentiate
the impact of novel agents upon distinctive NS sub-domains
like diminished emotioanal expression vs avolition which
will not necessarily be modulated in parallel, in line with
their distinct pathophysiological substrates (Section 3).
Second, trial failures can be demoralising when hopes
were high and studies well-designed and well-conducted,
as exempliﬁed by bitopertin. However, rigorous analysis of
full clinical data sets may reveal hidden beneﬁcial actions,
for example on sub-domains of NS or in speciﬁc subpopula-
tions – and even permit re-purposing towards alternative
pathologies. Additional clinical and experimental explora-
tion of the “NMDA/glycine” hypothesis may reorient “R and
D” in a more promising direction – in the case of bitopertin,
one might argue, from glycine towards D-Serine based
therapies (Section 4.5). Mirroring a plethora of recent trials
of potential pro-cognitive agents, bitopertin was tested in
association with conventional antipsychotics but they may
well interfere with any beneﬁcal inﬂuence on impaired
neurocognition, NS and deﬁcits in social cognition (Section
2.1) (Millan et al., 2012). Two non-exclusive solutions may
be evoked. (1) Integrate a novel and promising mechanism
of action into a multi-target proﬁle incorporating several
complementary pharmacological properties to underpin
efﬁcacy against NS and likewise control other classes of
symptom. (2) Should a new agent (mono or multitarget) not
be suited to the control of positive symptoms, the drug
concerned can be tested either in patients presenting with
persistent NS or during the prodrome: in the latter instance,
it would relieve the distress of prominent NS and potentially
reduce transition to frank psychosis (Fusar-Poli et al.,
2013a; Sabbag et al., 2011).
Third, as indicated above, pharmacotherapy is not the
only avenue towards improved therapy for NS: alternativestrategies warrant systematic evaluation from cortical
stimulation, to a suite of “cognitive-behavioural-psycho-
social” interventions exploited alone and/or in “packages”
(Elis et al., 2013). As argued elsewhere for other classes of
symptom – and disorder (Chou et al., 2012; Millan, 2006,
2012; Valencia et al., 2013) – it may prove more productive
to consider the association of a new pharmacological
mechanism of action with a non-pharmacotherapeutic
strategy for optimal expression of advantages, rather than
persisting in adjunctive use with conventional antipsycho-
tics. Whether this goal is attainable in the course of initial
clinical development remains to be seen but, as indicated
above, imaginative trial design together with support
from regulatory agencies could eventually make such
studies, like drug evaluation in the prodrome, a realistic
proposition.
Finally, improved knowledge of the pathogenesis of NS in
terms of the cerebral circuits involved and their molecular
underpinnings will hopefully reveal novel targets for
improved pharmacotherapy (Table 2). In addition to increas-
ingly reﬁned studies in patients, success will depend upon
the progressive improvement of animal models, as outlined
in the following section.
5. Experimental studies of negative
symptoms: readouts and animal models
5.1. Animal models for studying NS: general
considerations
As intimated in the previous section, an important issue
addressed in this Special Volume is the use of experimental
paradigms for modelling NS, for elucidating their pathophy-
siological substrates, and for the identiﬁcation and valida-
tion of novel agents for their alleviation (Figure 6). It would
be naïve to imagine that one could fully reproduce NS and
the uniquely human condition of schizophrenia in an animal.
Accordingly, we are concerned with models for rather than
of NS and schizophrenia, and in each case designed to shed
light on speciﬁc underlying mechanisms and symptoms – it is
unlikely than any hypothetical “one-stop” paradigm will be
found. In this light, apart from core considerations of model
reliability and reproducibility, it is useful to keep in mind
the familiar criteria of: (1) face value (models for NS should
at least partially mirror observations in human patients);
(2) construct value (they should reproduce or mimic at least
certain pathophysiological (neural and neurochemical)
mechanisms underpinning NS) and (3) predictive value
(the inﬂuence of pharmacotherapy on measures for NS
should correlate with and anticipate clinical activity in
patients). The latter goal is the most challenging of all for
essentially any animal model, but particularly so for NS
since no robustly-active therapeutic agent is known (Section
4). As sketched out below and analysed in this Special
Volume, fulﬁlling the other two criteria is likewise anything
but straightforward (Der-Avakian and Markou, 2012;
Gururajan et al., 2010; Pratt et al., 2012; Trezza et al.,
2011a, 2011b).
The two interrelated and cores themes are. First, read-
outs relevant to NS, of which the most accessible in rodents
are social behaviour – as discussed by Wilson and Koenig
Models
(can be combined)
General read-outs
(preferably  multiple)
NS Sub-domains
(may overlap)
Pharmacologicala:
- NMDA antag.
- Cannabinoid (CB1) ago. 
- LSD
- Haloperidol?
Geneticb:
- Neuregulin-1 OE/KO
- MHC-2 KO
- D2R OE/D3R OE
- NMDA (NR1) KD
- Oxytocin R KO
- CNVs (22q11.2)
Developmental:
- Prenatal stress
- Peri-natal Poly I:C
Neonatal VH lesions
- Neonatal PCP 
- Adolescent isolation
Behavioural:
- Locomotion (approach/exploration etc)
- Operant lever pressing
- Place conditioning - Maze learning
- ICSS - Sucrose consumption/preference (hedonic state)
- Communication - USV, tactile, olfactory
- Nest-building
Mechanistic (cells to circuits):
- Biochemistry 
- Neurochemistry (dialysis)
- Electrophysiology
- Structural/functional imaging
Asociality:
- Soc. preference
- Soc. interaction
- Soc. place pref
- Adolescent play
Blunted affect:
- USV
- Touch/grooming
- Body movements
- Gestures/Gazea
Amotivation/
Anhedoniab:
- PR responding (effort)
- Planned behaviour
- Adolescent play
- Sex. behaviours
aPrimates
bSingle gene -examples,
Copy Number Variants (CNV) 
aAcute, sub-chronic, long-
term and withdrawal
bAnticipatory
Figure 6 The diversity of experimental models and readouts available for experimental study of various sub-domains of NS.
While procedures for studying asociality and amotivation are fairly well-established, blunted affect is far less accessible – few
speciﬁc readouts have been proposed, and alogia may be inaccessible. In most published accounts, only one or two readouts have
been employed and a single model for schizophrenia, with little effort to interlink behavioural observations to potential neural
substrates. Hence, considerable work remains to be undertaken to improve the experimental study of the causes and modulation of
NS, and there are many promising opportunities for progress. Abbreviations not in text: OE, overexpression; KO, knockout, KD,
Knockdown (hypomorphic mice); R; Receptor; V Hipp, Ventral hippocampus; I:C, Inosine:Cytosine; Soc, Social; and PR,
Progressive ratio.
667Negative symptoms of schizophrenia(2014) – and motivation/reward-driven behaviour – as
considered by Barnes et al. (2014). Second, animal models
for the induction of NS-like behaviours provoked by
pharmacological (Neill et al., 2014), developmental
(O’Tuathaigh et al., 2014) and genetic (Moser, 2014) manip-
ulations. The following paragraphs: underscore the major
messages of these papers, present several procedures out-
side their scope, highlight some new and insightful observa-
tions, discuss prospects for improved experimental study of
NS and – a little provocatively – ask whether the endless
hand-wringing over the ostensibly unique difﬁculties faced
in setting up models and readouts of NS in animals is
genuinely legitimate compared to other cardinal symptoms
of schizophrenia.5.2. Models for NS compared to cognitive and
positive symptoms in rodents: a unique challenge?
As mentioned above, it is bemoaned – or at least intrinsi-
cally assumed – that modelling NS of schizophrenia is
inherently more complicated than other dimensions of the
disorder. However, it is worth reﬂecting as to whether this
genuinely the case, in particular in comparing NS to positive
symptoms.
Procedures for interrogating neurocognitive domains like
attention, working memory and executive function are
fairly well-established in rodents – with several translatable
to humans and their disruption can be studied in a variety ofexperimental models for schizophrenia, despite the con-
tinuing challenge of social cognition (Buchanan et al.,
2011b; Millan and Bales, 2013).
As regards positive symptoms, the tacit assumption is
that animal models are pretty undemanding. However, this
seems based on the unspoken notion that easy to treat in
patients must mean easy to model in animals. Yet, as
regards “face value”, delusional thinking and paranoia seem
quite a long way removed from motor readouts like climbing
behaviour (apomorphine), avoidance responses (condi-
tioned) and hyperactivity (psychostimulant-induced) in rats,
while recording head twitches in mice likewise seems a far
cry from auditory hallucinations in patients (Castagné et al.,
2009). These empirical measures reﬂect activation of D2
and 5-HT2A receptors, respectively, paralleling the antago-
nist properties of currently-used second generation anti-
psychotics at D2 and 5-HT2A receptors (Section 4.1)
(Meltzer, 2012). On the other hand, other mechanisms
involved in the induction of positive symptoms like disrup-
tion of GABAergic and glutamatergic transmission in FCX are
not integrated into these models. This is a critical point
since refractory patients may have a more “glutamatergic”
than dopaminergic pathology and it is the resistance to
treatment of positive symptoms in up to 30% of patients that
is the genuine problem today: this notion of construct
validity is poorly integrated into current models (Gilmour
et al., 2012; Hashimoto et al., 2013; Javitt, 2012; Leucht
et al., 2013; Poels et al., 2014). Though NMDA antagonists
are widely used for characterisation of drug actions against
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likewise have serious limitations (Javitt, 2012; Millan et al.,
1999; Pratt et al., 2012) and animal models for DA-
independent and refractory positive symptoms do not
appear to be even on the horizon.
Thus, we may be naive in considering models of positive
symptoms as unproblematic: other than predictively for
detecting D2 receptor blockade, they are well off the radar
as regards the current therapeutic need to ﬁnd agents of
greater efﬁcacy in resistant patients. In addition, run of the
mill models have tended to foster a mono-dimensional DA-
centric approach to treatment of positive symptoms and
drug screening for the best part of 50 years. Putative
models for positive symptoms irresponsive to D2 (and
5-HT2A) antagonists may be the way to go if we wish to
ameliorate treatment of positive symptoms. Yet it is pre-
cisely the criteria of good responsiveness to clinical-used
agents that paradoxically may be impeding progress in the
development of procedures for studying “resistance”. Lack
of effect of a clinically-used agent tends to downgrade the
model and render claims of positive actions of drugs with
novel mechanisms of actions suspect – at least in the eyes of
those making key decisions for drug development. Some-
thing of a Catch 22, since if the drug does actually work in a
conventional model it risks being unoriginal and lacking in
inherent advantages over existing agents.5.3. Readouts of NS-like behaviours in rodents
As for putative models for NS, the situation is radically
different: “validation” by agents robustly active in the
clinic is unfeasible – there simply are not any. Proof of
irresponsiveness to haloperidol and other currently-used
antipsychotics is simple to show, yet hardly convincing as
an alternative strategy. While a modest response to
clozapine, amisulpride, glycine reuptake inhibitors or
oxytocin might be considered as encouraging (Section
4), there are no persuasive means of therapeutically-
relevant, pharmacological validation. The predictive sta-
tus of animal work on NS is then, unfortunately, nebulous,
and will remain so until we ﬁnally ﬁnd medication that is
consistently effective against NS in patients. On the other
hand, there seems no reason not to promote the construct
validity of models and readouts by back-translating from
human work (Section 3) and evaluating the status of, for
example, frontocortical-temporal and cortico-striatal
networks; GABA-glutamate coupling; DA release, and
oxytocinergic transmission. This would necessitate an
overdue mechanistic expansion of readouts from the
behavioural measures classically used today (Figure 6).
For example, how do alterations in social motivation and
behaviour relate to oxytocin release and to electrophy-
siological measures of changes in fronto-temporal net-
work activity, and how do alterations in effort invested to
gain a reward relate to changes in the striatal release of
cannabinoids and altered fronto-striatal circuit function
(see further below, Section 5.8).
On the other hand, concerning face value, the status of
animal studies of NS may not be as disastrous as one might
think, despite the fact that our knowledge of their aetiology
is limited (Section 3). Most obviously, asociality is accessiblevia direct measurement of active social interaction
(Gururajan et al., 2010; Trezza et al., 2011a, 2011b) which
can be modiﬁed by a variety of manipulations from the pro-
psychotic agent, PCP (Neill et al., 2014), to developmental
(Moser, 2014) and genetic (O’Tuathaigh et al., 2014) models.
As discussed in these papers, and in the keystone article of
Wilson and Koenig (2014), it is crucial to control for the
inﬂuence of diverse factors that are not an intrinsic
component of the asociality of NS, like attention, motor
performance, sensory status, aggression and fear. The same
holds for studies of mice in which the widely used 3-
chamber test of social preference-sociability-social afﬁlia-
tion has been undertaken (Silverman et al., 2010; Millan and
Bales, 2013). In all procedures, as accentuated above, it is
important to control for the intertwined factor of social
cognition (Millan and Bales, 2013). In any event, from the
perspective of face value, social behaviour in rodents
clearly does provide a framework for examining the pertur-
bation and restoration of a core facet of NS, asociality.
As regards the hedonic state of consummatory pleasure
(liking), this is only modestly compromised in schizophrenia
whereas the anticipation of reward (wanting) and the
initiation of behaviours to acquire it are strongly impacted
(Foussias et al., 2014). Measures of each of these dimen-
sions of reward – and of the underpinning cognitive opera-
tions – have been well-studied in rodents, including social
reward (Trezza et al., 2011a, 2011b), as discussed by Barnes
et al. (2014).
To summarise, the study of NS is certainly not simple,
blunted affect still represents something of a conundrum
and alogia (strictu sensu) may be intransigent to investiga-
tion in rodents. Nevertheless, there are sufﬁcient experi-
mental handles for progress to be made, especially as
regards the sub-domains of asociality and amotivation
(Section 5.8). The principle handicap remains the lack of
an agent clinically effective against NS for test validation.5.4. Induction of NS-like behaviours in diverse
models for schizophrenia
Historically speaking, there has been a shift from pharma-
cological (psychostimulants, hallucinogens, NMDA antago-
nists etc.) to neurodevelopmental to genetic models for
schizophrenia, with a recent tendency to reassert the
primacy of developmental models and, ideally, to super-
impose them on a genetic background (Section 5.8.3).
Some environmental manipulations, like prenatal stress or
perinatal inﬂammation, are not speciﬁc for modelling
schizophrenia vs other psychiatric disorders – depression
and autism, respectively (Fatemi and Folsom, 2009; Meyer
and Feldon, 2010; Millan, 2013). Further, certain risk genes
like Disrupted in Schizophrenia-1 and Neuregulin-1 are
associated with other disorders – bipolar disorder and
autism, respectively (Meyer and Feldon, 2010; Millan
et al., 2012; Pratt et al., 2012; Sullivan et al., 2012). This
should be borne in mind in interpreting the signiﬁcance of
NS-like symptoms. It should also be stressed that devel-
opmental, genetic and pharmacological models usually
aim to mimic a risk factor posited to increase suscept-
ibility for – or even provoke – schizophrenia, rather than
just NS per se. In this sense, it might be argued that there
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like behaviours and responses are examined in parallel
with other symptoms and, over the past decade or so, the
emphasis has been on a positive-like phenotype and
neurocognitive disruption with only secondary attention
devoted to NS – and social cognition (Millan et al., 2012;
Pratt et al., 2012). This has somewhat biased the litera-
ture and even studies of social interaction (examined
fairly routinely) have often not been sufﬁciently rigorous
in dissecting out components directly related to NS, a
limitation articulated by Wilson and Koenig (2014), Moser
(2014), and O’Tuathaigh et al. (2014) in this volume.
Accordingly, despite a revival of interest in NS, the
literature is still fairly meagre as concerns their character-
isation in animal models for schizophrenia. Further,
very few studies have shown that NS-like observations can
be normalised by pharmacological treatment, and even
fewer have examined the actions of agents other than
antipsychotics.5.5. Social interaction and other measures of
social behaviour
5.5.1. Pharmacological procedures
Under conditions minimising anxiety, active and non-
aggressive social interaction is fairly straightforward to
record in rats, and it is consistently disrupted by acute
and sub-chronic administration treatment of NMDA recep-
tor open channel blockers like PCP and ketamine, with the
effects of long-term exposure sometimes outlasting
administration schedules (Gururajan et al., 2010; Koros
et al., 2007; Neill et al., 2010, 2014; Sams-Dodd, 1995;
Wilson and Koenig, 2014). This disruption of social inter-
action has frequently been termed “social withdrawal”,
though it is not obvious that any active process of “with-
drawal” per se is actually taking place, and it is difﬁcult
to assert with conﬁdence that diminished social motiva-
tion or reward is involved. Nonetheless, effects of NMDA
receptor antagonists appear to be speciﬁc and, in view of
their ability to induce NS in humans, it is not unreason-
able to consider this procedure as relevant to the
asociality of schizophrenia (Gururajan et al., 2010;
Javitt, 2012; Neill et al., 2014). Interestingly, and mirror-
ing their clinical proﬁles in patients, haloperidol does not
prevent perturbation of social interaction by PCP while
clozapine and second generation antipsychotics exert
inconsistent effects (Gururajan et al., 2010; Neill et al.,
2014; Wilson and Koenig, 2014). Curiously, amisulpride
does not appear to have been examined and, irrespective
of ambivalent clinical ﬁndings, the glycine reuptake
inhibitor, bitopertin, would be of interest to examine.
Conversely, there is evidence that 5-HT1A agonists coun-
ter impairment of social interaction by NMDA receptor
antagonists (Boulay et al., 2004) and Cholecystokinin
receptor 2 antagonists are likewise effective – since
benzodiazepines were inactive, their mutual anxiolytic
properties are presumably not relevant (Seillier et al.,
2013). Of special interest, oxytocin reverses the suppres-
sion of social interaction by PCP via an action in the
amygdala, one putative site of action for enhancement of
social behaviour: the actions of oxytocin are mimicked byvasopressin which, in a context-dependent manner, also
expresses pro-social properties (Goodson and Thompson,
2010; Katayama et al., 2009; Lee et al., 2005; Matsuoka
et al., 2005).
It may be remarked that antagonists at mGluR5 recep-
tors, which are functionally coupled to NMDA receptors
(Millan, 2005), likewise reduce social interaction in rats
though this potential model has not apparently been
exploited for the characterisation of mechanisms related
to NS (Koros et al., 2007).
As regards other mechanisms known to control social
behaviour (and reward) and relevant to NS, cannabinoids
are of particular interest in view of their effects in humans,
and since PCP decreases social interaction at least partially
by modulating endocannabinoid transmission in the PFC –
and probably amygdala (Seillier et al., 2010, 2013). Not
least as regards social behaviour, the pharmacology of
cannabinoids is complex (and confusing) but, as reviewed
by Gururajan et al. (2010), tetrahydrocannabinol (the main
active constituent of cannabis) and acute exposure to
synthetic agonists generally suppress social interaction.
Their effects are blunted by the (non-psychotropic) antago-
nist, cannibidiol, and by drugs interfering with endogenous
cannibinioid metabolism (Trezza and Vanderschuren, 2008).
Though the potential inﬂuence of cannibinoidergic mechan-
isms on anxiety should not be neglected, comparisons of the
modulation by cannibinoid agonists vs NMDA antagonists of
social interaction could offer novel insights into the origins
and control of NS (Almeida et al., 2013; Gururajan et al.,
2010; Seillier et al., 2010, 2013).
Another agent of interest is the hallucinogen, Lysergic
acid diethylamide (LSD), which behaves as a potent agonist
at 5-HT2A (and D2) receptors. LSD produces a discriminative
stimulus in rats which is potentiated by PCP (Winter et al.,
2000). Chronic exposure of rats to low doses of LSD leads to
impaired social interaction, and a broader phenotype
reminiscent of the effects of acute and sub-chronic treat-
ment with NMDA receptor antagonists. This includes: ele-
vated release of glutamate in the PFC; hyperlocomotion
(blunted by olanzapine and haloperidol); irritability,
enhanced aggression, and a reduction in sucrose consump-
tion suggesting an anhedonic state (Marona-Lewicka et al.,
2011). This model warrants further evaluation.
The 3 chamber test in mice has been widely used to
explore sociability, social preference, social motivation and
social novelty discrimination, albeit mainly in the ﬁeld of
autism (Silverman et al., 2010; Millan and Bales, 2013). In a
recent study, resistance to antipsychotics and sensitivity to
D-Cycloserine were used as criteria of “predictive” validity
to characterise a model of disruption of social preference by
pharmacological stimuli (Hanks et al., 2013). While these
criteria may be debatable (D-Cycloserine has only been used
adjunctively in humans and it is not consistently effective
against NS) (Section 4.6) (Davis et al., 2014; Javitt, 2012)
the ﬁndings are interesting. Thus, PCP was inactive,
whereas a GABAA inverse agonist diminished sociability
and its actions were blunted by D-Cycloserine, but neither
by clozapine nor the anxiolytic, alprazolam (Hanks et al.,
2013). In view of interest in GABAAα2 subunit agonists (not
unfortunately tested) for treating NS and other symptoms of
schizophrenia (Section 4.4), additional research with this
model is justiﬁed.
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Social interaction is the readout that has been most widely
exploited in early-life and adolescent neurodevelopmental
models for schizophrenia, employing a diverse suite of
perturbations from (1) prenatal stress and disruption of
neurogenesis to (2) perinatal ventral hippocampus lesions
(VHL) and exposure to viral mimics/pro-inﬂammatory
agents to (3) post-weaning isolation (Fatemi and Folsom,
2009; Fone and Porkess, 2008; Meyer and Feldon, 2010;
Piontkewitz et al., 2012; Pratt et al., 2012; Tseng et al.,
2009). A highly consistent observation has been reductions
in social interaction in adults, as discussed by Wilson and
Koenig (2014) and Moser (2014), in this Special Volume.
One interesting example is VHL in rats, which is usually
effected by local injection of isobotenic acid at post-natal
day 7. Decreases in social interaction are already seen
during adolescence (prior to the appearance of changes
related to positive symptoms) and they persist throughout
adult life (Tseng et al., 2009). Early emergence may be
related to prodromal NS in humans prior to the ﬁrst frank
psychotic episode (Fusar-Poli et al., 2013a, 2014). The
decrease in social interaction, which is antipsychotic-insen-
sitive, is accompanied by increased aggression and impaired
social memory, observations accentuating the point that
changes in a readout for “NS” should never be examined
independently of other behaviours when contemplating
their relevance (Pratt et al., 2012; Tseng et al., 2009).
More generally, it is important to conﬁrm, as has been
achieved in several studies, that alterations in social inter-
action can be dissociated from anxiety (Moser, 2014).
It is intriguing that VHL-induced decreases in social
interaction were attenuated by the neurotrophic agent,
cerebrolysin, which enhances synaptic plasticity in the PFC
and limbic structures (Vázquez-Roque et al., 2012, 2014).
Conversely, though few data with antipsychotics are avail-
able for developmental models, they do not seem to be
effective in reversing social interaction deﬁcits, including
those seen in the VHL paradigm (Koike et al., 2009; Lee
et al., 2007; Neill et al., 2014; Rueter et al., 2004; Tseng
et al., 2009). By analogy to pharmacological models of NS,
this lack of reversal by antipsychotics mirrors the situation
in patients, but deﬁcits in social interaction seen in a viral
model of perinatal inﬂammation were, contrariwise,
reversed by D-Serine (Nagai et al., 2012).
As for other behavioural readouts, reductions in social
preference in a 3 chamber test were seen in adult mice that
had undergone perinatal inﬂammation (Smith et al., 2007). In
this procedure, decreases in pup play were perhaps related,
like the adolescent reductions in social interaction following
VHL, to the high-risk prodromal state and justify further
exploration (Kirsten et al., 2010). Indeed, as cogently argued
by Trezza et al. (2011a, 2011b), adolescent play in rats (and
social proximity in mice) could be proﬁtably exploited to
characterise social motivation and reward in developmental
and other models of schizophrenia (Section 5.8).5.5.3. Genetic models: transgenic mice
Despite high heritability, the genetics of schizophrenia are
heterogeneous, complex and multi-factorial with a poly-
genic burden of minor risk factors distributed across hun-
dreds of genes in most patients, whereas a minority ofsubjects reveal (usually de novo) high-impact genetic
aberrations involving larger, structural (copy number) var-
iants. Not only protein-coding genes are implicated: for
example, there is a strong association between the micro-
RNA, miR137 – a regulator of cortical neurodevelopment –
and schizophrenia, though any speciﬁc role in the genesis of
NS awaits elucidation (Millan, 2013, Sullivan et al., 2012).
Note that many genetic risk factors for schizophrenia over-
lap with those for other developmental disorders and/or
bipolar depression (Andreassen et al., 2014; Malhotra and
Sebat, 2012; Purcell et al., 2014; Sullivan et al., 2012).
These elements complicate the generation of broadly-
relevant genetic models for schizophrenia and, to reiterate
the point made above, no genetic model has been described
that speciﬁcally and exclusively is aimed at reproducing NS.
Nonetheless, considerable progress has been made, as
expertly discussed by O’Tuathaigh et al., 2014 in this Special
Volume. Much experimental work has been inﬂuenced by
genetic susceptibility factors in patients, with several
recent studies focussing on: (1) genes revealed by
Genome-Wide (unbiased) Association Studies and (2) rare
Copy Number Variants (Hiroi et al., 2013; K.W. Lee et al.,
2012). Interestingly, the genes concerned tend to control
developmentally-regulated synaptic networks and signalling
plasticity, often with the participation of NMDA receptors.
Hence, genetic models for schizophrenia often converge
onto mechanisms targeted by pharmacological and devel-
opmental models.
Perhaps the best known Copy Number Variant linked to
schizophrenia is 22q11.2 where deletions and duplications
are also related to autism – including Di George syndrome,
which has an about 30 fold greater risk of schizophrenia
(Baker and Skuse, 2005; Hiroi et al., 2013; Malhotra and
Sebat, 2012, Millan, 2013). Many genes are involved in this
accrued risk of psychosis and the (not always “psychosis-
like”) behavioural changes in mice with manipulation of this
region, but of special interest is a 200 kB region containing
the Serp5 gene (Hiroi et al., 2013). Its overexpression
facilitates afﬁliative social behaviour whereas deletion
leads to its diminution and – further suggesting a link to
NS – delayed acquisition of rewarded approach behaviour
(Harper et al., 2012; Suzuki et al., 2009). This gene merits
additional analysis.
One of the most robust ﬁndings to emerge from Genome
Wide analyses was the association of several polymorphisms
in the developmentally-important Major Histocompatability
Complex (MHC) with schizophrenia (Andreassen et al., 2014;
K.W. Lee et al., 2012; Sullivan et al., 2012). Schnurri-2
(MHC-binding protein 2), constitutively binds to and inhibits
Nuclear Factor-kappa B which itself acts at the MHC
promoter to enhance gene expression. Schnurri-2 knockout
mice show widespread brain inﬂammation and GABAergic
interneurone down-regulation linking this model to devel-
opmental paradigms. Further, they reveal both anhedonia
(decreased sucrose consumption) as well as reduced nest-
building behaviour, a behavioural change related to NS and
observed in, for example, animals with disrupted NMDA
receptors and developmental models for schizophrenia
(Baharnoori et al., 2012; Halene et al., 2009; Takao
et al., 2013). Attenuation of deﬁcits in Schnurri-2 deﬁcient
mice by anti-inﬂammatory drugs reinforces the notion
that inﬂammation-related disruption of glutamatergic
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This is of interest in the light of clinical investigations of the
potential utility of cyclo-oxygenase inhibitors and minocy-
cline. The latter agent acts via anti-inﬂammatory mechan-
isms (though not exclusively) to exert a surprisingly
consistent pattern of efﬁcacy against NS in patients (Davis
et al., 2014; Dean et al., 2012; Khodaie-Ardakani et al.,
2014; Levkovitz et al., 2010; Liu et al., 2014; Monte et al.,
2013; Müller et al., 2013).
Another gene worth citing is Neuregulin-1 since, amongst
other actions, it is inhibitory to Src Kinase-facilitation of
NMDA receptor-mediated signalling and may be overex-
pressed in schizophrenia (Pitcher et al., 2011). Interestingly,
in line with the importance of correct gene dosage (Millan,
2013), both over and under-expression of the Neuregulin-1
gene in mice disrupts social behaviour, and the effects of its
genetic manipulation depend on the nature of the mutation,
underscoring the complexity of even single gene models for
studying NS (O’Tuathaigh et al., 2007, 2014).
As for glutamatergic transmission itself, there are fewer
data than might be imagined. Nonetheless, genetic disrup-
tion of D-Amino-Acid Oxidase (which catabolises D-Serine)
partially restores deﬁcits in social behaviour provoked by
mutations in the NMDA receptor subunit, “Grin1”, a point
worth underlining in light of positive data with D-Amino-Acid
Oxidase inhibitors against NS in patients (Labrie et al.,
2010; Lane et al., 2013). Along these lines, the gene
encoding the ionotropic GluD1 glutamate receptor is linked
both to schizophrenia and to anomalous operation of fronto-
thalamic networks (Nenadic et al., 2012). Its deletion is
associated with a reduction in social interaction abrogated
by D-Cycloserine (Yadav et al., 2012). Finally, the GABAB
receptor agonist, baclofen, opposed the reduced sociability
triggered by genetic deletion of the NR1 subunit of NMDA
receptors, likely by restoring NMDA-GABAergic and
excitatory-inhibitory balance in the cortex – the clinical
inﬂuence of GABAB agonists on NS remains, surprisingly,
unknown despite their current development for manage-
ment of autism (Gandal et al., 2012; Millan, 2013).
Though surprisingly little information pertinent to social
behaviour has emerged from genetic manipulation of dopa-
minergic transmission, mice with a null mutation for the DA
transporter showed a deﬁcit in the social transmission of
food preference. This alteration is clearly relevant to
impaired social cognition but is also of interest with regard
to NS since, like other deﬁcits, it was blunted by pregne-
nelone, a positive modulator of transmission at NMDA and
GABAA receptors under study for alleviation of NS in
patients (Sections 4.4 and 4.5) (Wong et al., 2012). As
regards DA receptors themselves, studies have to date
focussed more on their relationship to avolition than to
social behaviour (Section 5.6.4). Nonetheless, inasmuch as
D3 receptor over-expression decreases motivation, and D3
receptor inactivation is associated with enhanced social
novelty discrimination, social interaction and nest-building
behaviour in mice, further study of the signiﬁcance of D3
and other classes of DA receptor to asociality appears
warranted (Gross et al., 2013; Watson et al., 2012).
Finally, oxytocin has not unnaturally evoked considerable
interest, and genetic interference with oxytocin receptors con-
sitently disrupts social behaviour, cognition and communication
in mice with both homozygotes and – perhaps more speciﬁcally– heterozygotes displaying deﬁcits in both sociability and social
novelty preference (Goodson and Thompson, 2010: Millan and
Bales, 2012; Pobbe et al., 2012; Sala et al., 2013). Importantly,
these models exemplify the difﬁculty of extrapolating to any
speciﬁc diagnostic entity in humans since observations have
mainly been linked to autism rather than schizophrenia, despite
evidence that the latter disorder is characterised by defective
oxytocinergic transmission (Section 4.8) (Meyer-Lindenberg
et al., 2011).
5.5.4. Genetic models: speciﬁc mice strains
In addition to transgenic strategies, it is interesting to
consider the complementary “genetic” strategy of comparing
speciﬁc mouse strains.
For example, “reeler” mice are deﬁcient for the risk gene
reelin which is epigenetically silenced in GABAergic inter-
neurons both in the PFC of subjects with schizophrenia, and
in corresponding animal models (Millan, 2013; Pratt et al.,
2012). Reelin mice display reduced levels of oxytocin (Liu
et al., 2005; Millan, 2013) and, while NS like symptoms have
not yet been described, social withdrawal has been seen in
another instructive strain, “sandy” mice, deﬁcient in the
schizophrenia risk gene, dysbindin (Talbot, 2009).
As a further example, the “Black and Tan Brachyury”
(BTBR) inbred line has attracted particular attention. This
mouse displays a spectrum of deﬁcits in social behaviour,
sociability and social communication, including scent mark-
ing and Ultrasonic Vocalisations (USV), which collectively
underscore its pertinence to autism, as well as schizophre-
nia (Meyza et al., 2013; Scattoni et al., 2013; Yang et al.,
2013). Indeed, BTBR mice reveal decreases in grey matter
volume in the PFC and anomalies of white matter, recalling
observations in schizophrenic patients (Section 3.2) (Dodero
et al., 2013; Ellegood et al., 2013). The recent ﬁnding that
levels of kynenurenic acid are elevated in BTBR mice is
especially interesting (McTighe et al., 2013) since, as
mentioned above, this endogenous antagonist of NMDA
receptors has been implicated in the pathophysiology of
schizophrenia (Millan, 2005; Müller et al., 2013). Moreover,
the Glycine B/NMDA receptor partial agonist, D-cycloserine,
improved sociality in this strain (Burket et al., 2013).
Finally, in light of the implication of frontocortical mTOR
(mammalian target of rapamycin) over-activation in the
impairment of social cognition in schizophrenia (Meffre
et al., 2012), it is interesting that the inhibitor, rapamycin,
promoted sociability in BTBR mice (Burket et al., 2014)
It is not always evident to ﬁnd the right strain for
comparative studies, but more intensive characterisation
of BTBR and other inbred mice populations should provide
further insights into the origins and modulation of NS (Millan
and Brocco, 2008; O’Tuathaigh et al., 2014).
5.6. Amotivation, avolition and disruption of
anticipatory reward
5.6.1. Procedures for evaluating mechanisms
controlling reward, motivation and hedonic states
Generally speaking, deﬁcits in motivation have been less
extensively studied than disruption of social behaviour
in rodent models for schizophrenia. Nonetheless, data are
beginning to accumulate with clear indications of how
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entertained to a larger opus of data showing that dopami-
nergic pathways fulﬁl a crucial role in motivation and
reward processes: see articles by Neill et al., 2014, Moser,
2014 and O’Tuathaigh et al., 2014 in this Special Volume
and, in particular, that of Barnes et al., 2014 who authori-
tively discuss the surprisingly broad range of procedures
available to characterise reward-related deﬁcits in rodent
studies of NS.
Many studies have concentrated on sucrose consumption
and, in certain cases, intracranial self-stimulation as direct
measures of hedonic states. However, as discussed above
(Section 2.1), schizophrenic patients primarily display
impairments of motivation (anticipation, wanting) rather
than reward (experience, liking) (Table 1) (Foussias et al.,
2014; Huxley and Fonseca, 2014), which are differentially
integrated by corticlimbic circuits (Berridge et al., 2009;
Berridge and Kringelbach, 2013; Strauss et al., 2014).
Hence, experimental procedures that differentiate these
functions are especially signiﬁcant (Barnes et al., 2014;
Pratt et al., 2012). In the context of motivation for reward,
procedures reﬂecting the effort (physical and/or cognitive)
that a subject is prepared to invest to obtain a reward are
crucial: these include Progressive/Random Reinforcement
procedures where, for each successive reward, the work
(level presses needed) increases/varies (Bardgett et al.,
2009; Barnes et al., 2014; Ghods-Shariﬁ and Floresco, 2010;
Hosking et al., 2014; Salamone et al., 2012; Ward et al.,
2011). Finally, apart from cost, the element of delayed
gratiﬁcation, whereby a preference for a more substantial
yet later reward over a smaller yet more rapidly available
reward (“delayed discounting”) is likewise accessible to
experimental study (Barnes et al., 2014; Pittaras et al.,
2014). This is relevant to schizophrenics in which a pro-
spective (uncertain) reward may be undervalued, hence
diminishing motivation to invest in its acquisition (Gold
et al., 2013; Salamone et al., 2012; Strauss et al., 2014).5.6.2. Pharmacological models
As analysed by Neill et al., 2014, it has been suggested that
the suppression of sucrose preference in rats by acute
administration of (usually high) doses of ketamine and other
NMDA receptor open channel blockers may be pertinent to
the NS of schizophrenia. For example, Baird et al. (2008)
demonstrated a reduction in the intake of palatable solution
of sucrose without any speciﬁc interference with taste,
while Vardigan et al. (2010) reported that dizocilpine
reduced sucrose preference in a manner separable from
any interference with motor function: its actions were
blunted by D-Serine and clozapine, but not by haloperidol.
Inasmuch as NMDA antagonists manifest (rapid-onset) anti-
depressant properties, it seems unlikely that a depresso-
genic action is involved: indeed, deﬁcits in sucrose
preference associated with models of depression are alle-
viated by comparatively low doses of ketamine, a drug in
development for resistant depression (Ma et al., 2013).
Other studies suggest that chronic exposure to NMDA
antagonists leads to a post-withdrawal phase of anhedonia
in tests of sucrose consumption and intracranial self-stimu-
lation, possibly due to depletion of corticolimbic pools of DA
(Barnes et al., 2014; Jentsch et al., 1997; Millan et al.,1999; Millan, 2006). These observations merit further con-
sideration but they appear to principally effect a change in
consummatory as opposed to anticipatory anhedonia so
their genuine relevance to NS remains uncertain. Indeed,
Neill et al., 2014 mention that chronic PCP does not
interfere with anticipatory reward as measured in a Pro-
gressive Ratio model of motivation. On the other hand,
using a chronic intermittent protocol of PCP administration
and a T-maze with a choice between a high effort/high
reward vs low effort/low reward arm, rats opted for the
latter suggesting low motivation for investing effort to
attain the greater reward (Morris et al., 2005; Pratt
et al., 2012). Furthermore, as discussed by Barnes et al.,
2014, amphetamine-withdrawn rats show a reduction in
behaviour directed towards the performance of sexual
behaviour, rather than any deﬁcits in the act itself. The
anhedonic-like state that accompanies cocaine-withdrawal
has been related to activation of mesolimbic populations of
kappa opioid receptors: their blockade is associated with
antidepressant properties, but whether this mechanism
exerts a direct impact on NS remains to be elucidated
(Chartoff et al., 2012).
Finally, many elegant mechanistic studies have been
undertaken to examine neuronal circuitry implicated in
reward processes and potentially disrupted in NS: for
example, GABAergic inactivation of the PFC leads to altered
dopaminergic encoding of expected rewards (Jo et al.,
2013). However, such specialised procedures cannot realis-
tically be used for characterisation of potential pharma-
cotherapy on a broad scale.
Thus, currently there is no simple and well-established
pharmacological model for studying NS related to amotiva-
tion, but some promising avenues of research justify further
exploration. In future work, elements of anticipation and
effort invested to attain reward warrant more intensive
study (Section 5.8).5.6.3. Developmental models
Great care must be taken to ensure that a behavioural change
genuinely relates to a schizophrenia-like phenotype and speci-
ﬁcally to NS. An interesting example was provided above as
regards the altered social interaction seen in neonatal VHL rats,
and this model serves to illustrate the comparable complexity
of studies of reward mechanisms (Brady et al., 2008; Tseng
et al., 2009). Le Pen et al., 2002 showed that VHL subjects
display a diminished preference both for a saccharine solution
and for a conditioned place preference to amphetamine,
indicative of an impaired hedonic state (Trezza et al., 2011a,
2011b). However, it is unclear how this anhedonia relates to the
reward deﬁcits of NS in schizophrenia since this model did not
incorporate measures of anticipatory motivation. Conversely,
this dimension was addressed by Brady et al. (2008) using a
Progressive Ratio schedule to determine the effort and motiva-
tion that VHL rats were prepared to invest for attaining their
goal (an injection of methamphetamine), a model with greater
face value for NS. Ironically then, VHL rats actually worked
harder before responding was discontinued. This observation
was interpreted as reﬂecting an increase in the reward-
ing properties of methamphetamine – commensurate with
the comorbidity of addictive behaviour in schizophrenics
(Heidbreder and Newman, 2010). Nevertheless, it might
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of decreased sucrose consumption/amphetamine place-
preference in rodents to the NS of schizophrenia. Further work
is necessary to clarify this issue. Oddly enough, there are little
other data concerning NS-related changes in motivation with
developmental models of schizophrenia, a ﬁeld ripe for expan-
sion using procedures mentioned above and more comprehen-
sively discussed in Barnes et al. (2014).5.6.4. Genetic models
The preceding section evoked the important elements of
anticipation and motivation to work for reward, of which a
deﬁciency epitomises NS (see also Section 3.3). This pro-
vides a useful transition to several elegant and interrelated
studies of amotivation undertaken in rats with genetically-
manipulated D2 and, more recently, D3 receptors (Drew
et al., 2007; Li et al., 2011; Simpson et al., 2011, 2014;
Triﬁlieff et al., 2013; Ward et al., 2009, 2011).
Transgenic mice that selectively overexpress D2 receptors
on medium spiny neurones in the striatum may be compared
to the “overactivation” of subcortical dopaminergic trans-
mission seen in schizophrenia. These animals stop respond-
ing sooner in Progressive and Random Ratio schedules of
lever-pressing for food. This cannot be explained by satiety,
fatigue or lack of hedonic pleasure, rather to a lack of
willingness to work and to insensitivity to the value of
future reward, perhaps due to poor internal representation
or faulty computation of cost vs beneﬁt relationships (Drew
et al., 2007; Ward et al., 2012). This dissociation between
incentive motivation and hedonic appreciation of reward
resembles the proﬁle of NS in schizophrenia underscoring
the interest of the model (Table 1) (Kring and Barch, 2014;
Strauss et al., 2014). The effects of striatal D2 receptor
overexpression likely involve a frontocortico-striatal loop
and disruption of excitatory-inhibitory signalling in the PFC
(Li et al., 2011), supporting relevance to the induction and
expression of NS (Section 3).
As regards potential modulation, 5-HT2C receptors were
up-regulated in the striatum of D2 receptor overexpressing
mice, and 5-HT2C receptor antagonists rescued the
decreased motivation (Simpson et al., 2011). Accordingly,
it was posited that 5-HT2C receptor antagonists may be
useful for restoring motivation in schizophrenia. However,
despite concomitant beneﬁts for moderating social anxiety
and depression, there is a risk of exacerbating positive
symptoms since 5-HT2C receptors inhibit mesolimbic
release of DA (Dekeyne et al., 2000, 2008; Meltzer, 2012;
Millan, 2006). Indeed, this was the basis for proposing 5-
HT2C agonists for the treatment of schizophrenia and, very
recently, the ﬁrst clinical data were released with tentative
improvement of both positive symptoms and, surprisingly,
NS (Shen et al., 2014). Thus, the status of 5-HT2C receptors
as a target for the control of NS and other dimensions of
schizophrenia awaits further clariﬁcation (Section 4.3).
More recently, another model was introduced in which a
lentivirus elicited (more pronounced) D2 receptor over-
expression speciﬁcally in the nucleus accumbens and, in
contrast to the above model, motivation to work to obtain a
reward was enhanced, with no change in consummatory
behaviour. This observation mirrors the increased motiva-
tion produced by enhanced mesolimbic release of DA inhumans and animals, and provides a counterpart to its
diminution by DA antagonists (Salamone et al., 2012;
Barnes et al., 2014; Triﬁlieff et al., 2013). The data are
also globally consistent with the use of psychostimulants to
alleviate NS (Lindenmayer et al., 2013). However, the data
also emphasise that: (1) at ﬁrst site similar models can show
important differences; (2) the role of DA in reward mechan-
isms is complex and regionally-speciﬁc and (3) direct
exploitation of dopaminergic substrates for the control of
NS might need to be local. This presents a formidable if not
insuperable therapeutic challenge – further underlined by
the central importance of D2 receptor blockade in the
control of positive symptoms.
A ﬁnal and rather more auspicious, dimension of
complexity is provided by the contrasting roles of D3
receptors – which are not differentiated from D2 recep-
tors by any antipsychotic currently available for pre-
scription (Millan and Brocco, 2008). D3 receptor
overexpression restricted to the striatum led to
decreased motivation in a Progressive Ratio schedule of
reinforcement (Simpson et al., 2014). This observation is
important since it suggests that blockade of striatal D3
receptors may counter the amotivation of schizophrenia.
Several other observations suggest that D3 receptor
blockade should counter NS, such as facilitation of
nesting behaviour and social contact (Gross et al.,
2013). Moreover these actions are complemented by a
PFC-mediated and broad-based enhancement of social
cognition and multiple neurocognitive domains (Table 2)
(Gross et al., 2013; Millan et al., 2007; Millan and
Brocco, 2008; Nakajima et al., 2013; Watson et al.,
2012). D3 receptor blockade also counters co-morbid
drug-seeking behaviour, though hypothesised beneﬁts for
the control of positive symptoms await clinical evalua-
tion (Gross et al., 2013; Heidbreder and Newman, 2010;
Millan and Brocco, 2008; Mugnaini et al., 2013). Bizarrely
enough, despite the availability of well-tolerated and
thoroughly-characterised D3 receptor antagonists, their
inﬂuence on NS has never been speciﬁcally determined
at appropriate doses (op. cit.).
Despite this intriguing and extensive body of data concern-
ing dopaminergic mechanisms, disappointingly few data are
available concerning NS-related impairment of motivation
from other genetic models for schizophrenia (O’Tuathaigh
et al., 2014).5.7. Blunted expression: procedures and readouts
of potential utility
In a sense, rodents “speak to us with their feet”, so their
(loco)motor behaviour is an expression of their emotional
and internal state (Figure 6). Hence, behaviours like
decreased sociability and social interaction, reduced lever
pressing for reward and decreased anticipatory approach
behaviour may at least partially reﬂect blunted expression
(Barnes et al., 2014; Wilson and Koenig, 2014). However,
this possibility does not appear to have been formally
addressed, nor this sub-dimension of NS factored out in
studies evoked above. Furthermore, there appears
to be no currently-accepted and broadly-used readout
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models. The following points are nevertheless of interest.
There are indications that ketamine induces emotional
blunting in humans (Abel et al., 2003; Millan, 2005) and its
disruption of amygdala-integrated fear conditioning in rats,
as measured by both behavioural and neurochemical mea-
sures, was proposed as a measure of emotional blunting
irresponsive to conventional antipsychotics (Pietersen
et al., 2007). However, it is hard to be certain that this
model relates to NS rather than modulation of anxiety per
se and further validation is awaited before its utility can be
more rigorously assessed.
Likewise, though increased immobility in a forced swim-
ming test following chronic exposure of NMDA antagonists
has been considered analogous to the induction of “emo-
tional blunting” in schizophrenia, the speciﬁcity and perti-
nence of this readout remains debatable (Neill et al., 2014).
Though the induction of immobility by neuroleptics/D2
receptor blockade might be claimed as related to “second-
ary NS”, it is hard to differentiate a putative impact of
drugs on motor behaviour, depressed mood and other
factors from any putative induction of “emotional blunt-
ing”. Nonetheless, the enhanced immobility associated with
chronic exposure to PCP was reversed by D-Cycloserine (and
sub-chronic clozapine, but not haloperidol) suggesting that
further study is warranted (Murai et al., 2007; Turgeon
et al., 2007).
The procedures outlined above, despite their interest,
still require more rigorous characterisation, so several other
approaches of potentially greater face validity for examin-
ing blunted expression are evoked below (Section 5.8.2).5.8. Prospects for further reﬁnement of
experimental studies of NS
5.8.1. Major lines of study to date and possible
extensions: motivation and social interaction
From the above discussion, it is apparent that a surprisingly
broad range of readouts and measures are potentially
available for examining social behaviour, reward and moti-
vation in rodent models for schizophrenia (Figure 6) (Lai
et al., 2014; Lahvis et al., 2011; Markou et al., 2013;
Silverman et al., 2010; Trezza et al., 2011a, 2011b;
Tzschentke, 2007). On the other hand, the number of
pharmacological mechanisms suggested to actually modify
NS-like behaviours in animal models (Table 2), and the
breadth of measures exploited to date is fairly restricted.
For example, little has been done as regards amotivation
in developmental and genetic models. Measures of sucrose
consumption as a readout of hedonic states (consummatory
reward) have been (questionably) prioritised and, even in
pharmacological models, the rich repertoire of procedures
for differentiating changes in anticipatory vs consummatory
anhedonia has been under-utilised. Though the specialist
nature of some behavioural paradigms may admittedly be
dissuasive for neophytes, there is clearly much that could be
undertaken (Barnes et al., 2014; Pittaras et al., 2014).
As regards social behaviour, social interaction has greatly
predominated as a readout (not invariably with rigorous
controls for interference by factors like social anxiety and
social cognition), and tests of sociability and social noveltypreference etc. in mice have been comparatively little
adopted (Silverman et al., 2010; Trezza et al., 2011a,
2011b). Social motivation is a particularly interesting area
for improved future study. Trezza et al. (2011a, 2011b)
pointed out that maternal pup care, sexual behaviour and
play are all highly motivating in post-partum females, adults
and adolescents/juveniles, respectively. The latter two
behaviours could be instructively employed in experimental
studies of NS in rats, employing either operant, maze-based
and or place-conditioning paradigms – for adolescent mice,
social proximity would be the readout. For example, in a
conditioned social place preference procedure, rats pre-
ferred a compartment previously associated with a social
partner compared to one where it was absent (Tzschentke,
2007). This preference is disrupted by sub-chronic PCP,
and further exploration of this procedure would be of
considerable interest (Schwabe et al., 2006; Thiel et al.,
2008). Learning in T-maze models is also of interest in light
of the need to remember and recall past rewarding experi-
ences in order to anticipate, positively value and strive for
potential future rewards (Berridge et al., 2009; Berridge
and Kringelbach, 2013; Kring and Barch, 2014; Trezza et al.,
2011a, 2011b).
There are ample opportunities for substantially enriching
studies of social motivation and reward in animal models for
schizophrenia focussing on NS.5.8.2. Alternative approaches to evaluating diminished
emotional expression
As pointed out in Section 5.7. there is considerable room for
improvement as regards the NS sub-dimension of decreased
expression.
One human trait poorly back-translatable into animals is
fully syntactical, recursive and abstract language (Fitch
et al., 2010; Poeppel, 2012), of which a loss of ﬂuent
production (alogia) characterises NS (Table 1) (Foussias
et al., 2014). While the full complexity of verbal language
– and non-verbal visual signals – cannot be studied in
rodents, there are other modes of social communication
that could prove instructive, such as the olfactory and
tactile: mutual grooming in rodents – and primates – is
promoted by oxytocin and relevant both to restricted
expression and to asociality (Dunbar, 2010). The most
dynamic, pro-active and rich mode of exchange is arguably
USVs. USVs are emitted in a context and emotional state-
dependent manner, notably during tests of social preference
and social interaction amongst adults and/or pups, and in a
manner inﬂuenced by genetic background. Thus, the mon-
itoring of USVs (quantity, spectral distribution, pattern) and
their modulation during tests of social contact could provide
major insights relevant to decreased expression – as well as
social motivation and engagement – though extrapolation of
ﬁndings to human speech (alogia) should be made with great
caution, if at all (Lahvis et al., 2011; Nikiforuk et al., 2013;
Woḧr and Schwarting, 2013; Yang et al., 2013). Under-
pinning the interest of such work, altered emission of
USV accompanies reduced social interaction, disruption of
nest-building behaviour and compromised subcortical dopa-
minergic transmission in models of pre-natal infection/
inﬂammation (Baharnoori et al., 2012; Kirsten et al.,
2010, 2012). Tactile and USV means of communication – as
675Negative symptoms of schizophreniawell as yawning – have been advocated for studies of social
cognition and could well prove useful in work on NS in
rodents (Millan and Bales, 2013).
Facial expressions and licking patterns have been mon-
itored during consumption of rewarding and aversive solu-
tions, so it would be worth assessing a putative role in the
active transmission of affective state to conspeciﬁcs
(Berridge et al., 2009; Lydall et al., 2010; Peciña and
Smith, 2010).5.8.3. Combinations of developmental and genetic
models in rodents
In much the same way that studies of individual risk genes in
humans are migrating to analysis of epistatic interactions
between genes (Purcell et al., 2014; Sullivan et al., 2012),
there is a move to combine risk factors as a more realistic
approach for generating core feature of schizophrenia in
rodents (O’Tuathaigh et al., 2014; Hida et al., 2013). While
double genetic manipulations are feasible, of greater inter-
est are studies were the interface between genetic and
environmental risk factors has been mimicked by super-
imposing a developmental insult upon a vulnerable genetic
background. In one particularly interesting example,
Desbonnet et al., 2012 showed that social defeat in
adolescent mice synergistically impaired social interaction
when performed in subjects bearing a deletion of the gene
encoding Neuregulin-1. Further, other studies have
exploited mice with mutated genes for the risk gene,
Disrupted in Schizophrenia-1, and combined this genetic
background with perinatal inﬂammation. This dual-hit para-
digm is especially interesting since inﬂammatory mechan-
isms converge on many intracellular signals that interact
with this protein (Abazyan et al., 2010; Kamiya et al.,
2012). It was accompanied by reductions in social prefer-
ence and social interaction, observations unaffected by
antipsychotics (Nagai et al., 2011). Models combining risk
factors seem a particularly fruitful direction for additional
study since they are more faithful to multi-hit concepts of
the origins of schizophrenia (Figure 1).5.8.4. Induction of pathophysiological mechanisms in
discrete brain regions
A likewise novel yet rather different approach, mirroring
VHL in rats (Tseng et al., 2009) and inactivation of GABAer-
gic transmission in the PFC (Jo et al., 2013), consists in the
induction of pathophysiological mechanisms in discrete
brain regions to more precisely deﬁne the neural substrates
underlying NS. For example, localised expression of a
dominant-negative Disrupted in Schizophrenia-1 mutant
gene in mouse PFC provoked oxidative stress and beha-
vioural changes reminiscent of NS, including aberrant social
behaviour and reduced performance in a operant procedure
of effort-related reward procurement (Johnson et al.,
2013). Further, not just genetic manipulations are con-
cerned. For example, rather than induction of systemic
inﬂammation, intra-hippocampal injection in neonatal rats
of the pro-inﬂammatory agent, lipopolysaccharide, led to
microglial activation and deﬁcits in adult social behaviour
(Zhu et al., 2014).5.8.5. Alternative species: from primates to zebraﬁsh
models
Certain parameters relevant to social motivation and com-
munication, and interlinked both with NS and social cogni-
tion, cannot realistically be modelled in rodents, most
obviously those pertaining to the visual domain. This raises
the possibility of studies in non-human primates. For
example, analysis of gaze-following has been forwarded as
a strategy for improving our understanding of social cogni-
tion, and opportunities likewise may arise in primates for
gaining insights (behaviour, imaging, EEG etc.) into the
asociality of NS and its modulation (Millan and Bales,
2013). In addition, primates have been employed for
analysing the role of PFC sub-territories and the amygdala
in social motivation and reward-guided behaviour, processes
disrupted in schizophrenia (Murray and Rudebeck, 2013)
(Section 3.3). Social interaction (cognition) is well-studied
in primates (Byrne and Bates, 2010), and the interplay
between dopaminergic transmission and social hierarchies
has been explored in relation to cocaine reward, providing
another experimental template of potential relevance to NS
(Nader et al., 2012). A further possibility may be studies of
the social effects of ketamine, which has been exploited as
a pharmacological mimic for schizophrenia in studies of
cognitive performance and ERPs in primates (Gil-da-Costa
et al., 2013; Nakako et al., 2013). As recently reviewed
elsewhere (Millan and Bales, 2013), and mirroring models in
rodents, developmental procedures in primates involving
induction of inﬂammation, disruption of neurogenesis and
early-life cerebral lesions could be expanded for the
investigation of NS. Such studies must only be undertaken
in specialised labs, with rigorous ethical precautions, and
preferably with freely-moving subjects in a naturalistic and
highly social environment, and they should best be kept to a
minimum. Nonetheless, they could prove crucial for valida-
tion of novel therapeutic concepts, and in a translational
context before advancing a promising agent into humans for
potential relief of NS.
In a mirror image of the primate, there is increasing interest
in zebraﬁsh for the rapid screening of potentially-novel
psychotropic drugs, and for enhancing our understanding
of the cellular origins of neurodevelopment disorders like
schizophrenia (Maaswinkel et al., 2013; Norton, 2013). Genetic
homology is substantial with mammals and gene-manipulations
are rapid and straightforward; glutamatergic and dopaminer-
gic mechanisms are well characterised; reward and social
behaviour can be monitored; and administration of ketamine is
known to disrupt social interaction and the dynamics of social
groups, with its actions blunted by sulpride – but not
haloperidol (Collier and Echevarria, 2013; Seibt et al., 2011;
Zakhary et al., 2011). Once novel mechanisms for potentially
modulating NS have been identiﬁed in higher species, zebraﬁsh
may prove a useful initial model for screening the correspond-
ing drugs.5.8.6. More intensive linking of behavioural
observations to mechanistic bases
Apart from the above-mentioned importance of enriching
behavioural readouts, it would also be advantageous to
more closely link behavioural indices of NS to their potential
neural and neurochemical substrates using structural and
Table 3 Overview of core themes and observations addressed in this Special Volume, and of major questions under study.
Theme (Special
Volume, focussed
article)
Core issues addressed in this article and the Special Volume Key questions
(mostly outstanding)
Clinical
characteristics
of NS in relation
to other classes
of symptom
(1–5)
Core features of
schizophrenia, major
socio-economic burden,
still a major therapeutic
need.
Diagnostic criteria for
NS: two major sub-
domains, and advent of
DSM-5. Primary vs
secondary NS – hard to
distinguish despite
contrasting causes.
Measurement of NS,
importance of new rating
scales. Evaluation of NS
in therapeutic trials.
Studies of persistent NS,
and of NS during
prodromal phase in
subjects at risk of
transition.
What is the relative
contribution of primary
and secondary forms of
NS in patients?
What is the precise
relationship between
NS, impaired social
cognition and other
symptoms?
Clinical proﬁle of NS: real
world function severely
affected.
Is the deﬁcit syndrome a
genuine entity?
Why (and how) do NS
occur in other
psychiatric and
neurological disorders?
Pathophysiological
mechanisms
underlying sub-
domains of NS
(4,7)
Neural substrates and
cerebral circuits
implicated in NS. Pivotal
roles for frontocortico-
temporal cortices and
cortico-striatal loops.
Ventral and dorsal
striatum dysfunction
central to amotivation
and anticipatory
anhedonia. Other
regions: amygdala etc.
Neurochemical and
cellular substrates of
dysfunctional networks.
Key signiﬁcance for
glutamate, DA, oxytocin
and cannabinoids in
reward and social
function.
Use of structural and
functional imaging,
electrophysiology,
Magnetic Resonance
Spectroscopy and other
techniques to identify
networks, structures and
neuromodulators
implicated in NS. Time of
onset: mainly prior to
diagnosis.
Which
pathophysiological
mechanisms are speciﬁc
to NS vs other classes of
symptoms?
How can we better
deﬁne the molecular
and neurochemical
bases of NS and link
them to alterations of
neural circuits?
Are changes seen in
schizophrenia not only
causal to, but also
counter-regulatory of
NS?
Are mechanisms causing
NS the same as those
maintaining them?
Clinical treatment
and potentially
improved
control of NS (5)
Impact of currently-
available (5-HT2A4D2)
antipsychotics on NS.
Potential utility of other
classes of medication
(antidepressants and
anxiolytics).
Novel mechanisms of
action in development;
Oxytocin, GABAA and
glutamatergic agents,
increased frontocortical
DA release, minocycline.
Non-
pharmacotherapeutic
strategies: electrical-
magnetic “stimulation”
of cortex, and cognitive-
behavioural-psychosocial
therapies.
Can we identify novel
medication targets?
What are the relative
merits/drawbacks of
pharmacotherapy vs
other approaches, and
can we adopt and
validate combined
treatments?
Are agents that
exclusively improve NS
useful?
Would pre-diagnostic
treatment of NS (and
social cognition) reduce
transition to psychosis?
Experimental
models and
readout for
studying NS,
prospects for
progress (6–10)
Readouts of distinct
components of NS:
asociality (most studied);
amotivation, (complex
but accessible) and
blunted affect
Validation of procedures
and models: face value
(resemblance to clinical
NS); aetiological value
(underlying mechanisms)
and predictive value
Actions of clinically-used
antipsychotics,
glutamatergic
modulators and other
classes of agents. Most
data for acute
Can we identity
translational readouts
of NS sub-domains for
use in clinical drug
testing?
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Table 3 (continued )
Theme (Special
Volume, focussed
article)
Core issues addressed in this article and the Special Volume Key questions
(mostly outstanding)
(few data).
Pharmacological,
developmental and
genetic models for
induction of NS.
(drug actions predicts
clinical efﬁcacy).
administration to adult
rodents, with only one
model and/or readout:
few data for prodromal
administration.
How can we better
couple behavioural
measures of NS to
neurochemical,
biochemical and
electrophysiological
substrates?
How should we best
combine risk factors to
improve experimental
models of NS?
What is the utility of
non-rodent species?
The numbers refer to the papers of this Special Volume dedicated to the issues speciﬁed. (1) Foussias et al. (in press), (2) Malaspina
et al. (in press), (3) Marder and Kirkpatrick (in press), (4) Kring and Barch (in press), (5) Davis et al. (in press), (6) Wilson and Koenig
(in press), (7) Barnes et al. (in press), (8) Moser (in press), (9) O’Tuathaigh et al. (in press) and (10) Neill et al. (in press). The present
paper, in addition to a synthetic overview of all the themes speciﬁed above, discusses the neural and neurochemical substrates of NS,
a topic not covered in detail in the other papers, and the same holds for cognitive-behavioural-psychosocial therapies for
controlling NS.
677Negative symptoms of schizophreniafunctional imaging, electrophysiological parameters, and
dialysis measures of the release of glutamate, DA and
oxytocin etc.: such work is being intensiﬁed (Murai et al.,
2007; Neill et al., 2010; Piontkewitz et al., 2012; Pratt
et al., 2012). While the focus here (and elsewhere) has very
much been on glutamategic and dopaminergic mechanisms,
together with oxytocin where the interface with social
cognition is concerned, there should be greater attention
to other relevant cellular mechanisms modulating reward
and social behaviour, and potentially related to core
features of NS.
For example, cannabinoids may transduce the impact of
PCP on social behaviour in rodent models and they interact
with corticolimbic dopaminergic transmission and control
reward mechanisms. Further, cannabidiol (which enhances
endogenous levels of anandamide) reduced NS and other
symptoms in a small trial in schizophrenic patients, while an
increase in the nucleus accumbens density of CB1 receptors
has been correlated with the intensity of NS in patients
(Section 3.6) (Ceccarini et al., 2013; Leweke et al., 2012;
Seillier et al., 2010, 2013).
It is likely that we have still only identiﬁed a small
minority of endogenous mechanisms potentially exploitable
by pharmacotherapy for the improvement of NS in schizo-
phrenia (Table 2).5.8.7. Evaluating novel mechanisms for potentially
preventing NS
Drug treatments have almost invariably been undertaken in
adults upon acute administration, and after the appearance
of changes reﬂecting psychosis. It should be evaluated
whether longer-term administration of agents to adolescent
subjects prior to the appearance of positive-like symptomsin adults may: (1) alter those components of NS already
present and (2) hinder their emergence and progression in
adults. This would be analogous to the study in models for
schizophrenia of potential strategies for preventing the
onset of structural changes and cognitive impairment
(Clifton et al., 2013; Piontkewitz et al., 2012). Indeed,
more generally, there is a need to intensify studies of animal
models during (and just after) the adolescent phase when
NS-like changes may be apparent or emerging, even prior to
the manifestation of changes related to positive symptoms.
Finally, while it might be assumed that only pharma-
cotherapeutic approaches can be evaluated for their poten-
tial efﬁcacy against NS – or for impeding the development of
NS – recent work suggests that experimental models may
also be amenable to the study of “cognitive-behavioural-
psychosocial” strategies for preventing the emergence of NS
(H. Lee et al., 2012).6. Concluding comments
As summarised in Table 3, and more comprehensively
articulated in the individual articles of this Special Volume,
the current lack of effective treatment for the debilitating
NS accompanying schizophrenia has triggered considerable
efforts to: reﬁne their clinical characterisation and mea-
surement; deepen our understanding of the neural and
neurochemical substrates of NS; improve the performance
of clinical trials for innovative and potentially superior
therapy; explore clinical strategies for controlling NS com-
plementary to pharmacotherapy; and to broaden and
advance animal models and readouts for the experimental
study of NS. This all remains very much a “work in
progress”, many fundamental questions await elucidation,
M.J. Millan et al.678and the kinetics and complexities of rigorous clinical
characterisation of novel medication for NS are likely to
remain largely incompressible (Table 3). Nonetheless, pre-
competitive, industrial–academic–governmental initiatives
like “MATRICS” (US) and the Innovative Medicines Initiative
(EU) are proving increasingly beneﬁcial for target charac-
terisation and the development of clinical biomarkers,
while an on-going dialogue with the Federal Drug and
European Medicines Agencies is likewise useful in the design
of clinical trials for the improved control of NS. Overall,
there are grounds for cautious optimism.
Our knowledge of the causes, characteristics and potential
control of NS – and other facets – of schizophrenia is system-
atically progressing. While much remains to be learned, this
affords some hope that we should eventually be in a position
to propose novel strategies for the more effective treatment
of NS and other symptoms of this devastating disorder.
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Hoyer, C., Klosterkoẗter, J., Hellmich, M., Koethe, D., 2012.
Cannabidiol enhances anandamide signaling and alleviates psy-
chotic symptoms of schizophrenia. Transl. Psychiatry 2, e94.
Lewis, D.A., 2012. Cortical circuit dysfunction and cognitive deﬁcits
in schizophrenia – implications for preemptive interventions.
Eur. J. Neurosci. 35, 1871–1878.
Li, Y.C., Kellendonk, C., Simpson, E.H., Kandel, E.R., Gao, W.J.,
2011. D2 receptor overexpression in the striatum leads to a
deﬁcit in inhibitory transmission and dopamine sensitivity in
mouse prefrontal cortex. Proc. Natl. Acad. Sci. USA 108,
12107–12112.
Lin, C.H., Huang, C.L., Chang, Y.C., Chen, P.W., Lin, C.Y., Tsai, G.
E., Lane, H.Y., 2013. Clinical symptoms, mainly negative
symptoms, mediate the inﬂuence of neurocognition and social
cognition on functional outcome of schizophrenia. Schizophr.
Res. 146, 231–237.
Lincoln, T.M., Mehl, S., Kesting, M.L., Rief, W., 2011. Negative
symptoms and social cognition: identifying targets for psycho-
logical interventions. Schizophr. Bull. 37, S23–S32.
Lindenmayer, J.P., Nasrallah, H., Pucci, M., James, S., Citrome, L.,
2013. A systematic review of psychostimulant treatment of
negative symptoms of schizophrenia: challenges and therapeutic
opportunities. Schizophr. Res. 147, 241–252.
Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Xie, L., Zhang,
L., Yang, L., Yang, S., Yang, J., Ruan, Y., Zeng, Y., Xu, X., Zhao, J.,
2014. Minocylcine supplementation for treatment of negative
symptoms in early-phase schizophrenia: a double blind, rando-
mized, controlled trial. Schizophr. Res. (2014).
Liu, W., Pappas, G.D., Carter, C.S., 2005. Oxytocin receptors in
brain cortical regions are reduced in haploinsufﬁcient (+/)
reeler mice. Neurol. Res. 27, 339–345.
Loiseau, F., Dekeyne, A., Millan, M.J., 2008. Pro-cognitive effects of
5-HT6 receptor antagonists in the social recognition procedure in
rats: implication of the frontal cortex. Psychopharmacology 196,
93–104.Lydall, E.S., Gilmour, G., Dwyer, D.M., 2010. Analysis of licking
microstructure provides no evidence for a reduction in reward
value following acute or sub-chronic phencyclidine administra-
tion. Psychopharmacology 209, 153–162.
Ma, X.C., Dang, Y.H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.G.,
Hashimoto, K., 2013. Long-lasting antidepressant action of
ketamine, but not glycogen synthase kinase-3 inhibitor
SB216763, in the chronic mild stress model of mice. PLoS One
8, e56053.
Maaswinkel, H., Zhu, L., Weng, W., 2013. Assessing social engage-
ment in heterogeneous groups of zebraﬁsh: a new paradigm for
autism-like behavioral responses. PLoS One 8, e75955.
Maat, A., Fett, A.K., Derks, E., GROUP Investigators, 2012. Social
cognition and quality of life in schizophrenia. Schizophr. Res.
137, 212–218.
Makris, N., Seidman, L.J., Ahern, T., Kennedy, D.N., Caviness, V.S.,
Tsuang, M.T., Goldstein, J.M., 2010. White matter volume
abnormalities and associations with symptomatology in schizo-
phrenia. Psychiatry Res. 183, 21–29.
Malaspina, D., Walsh-Messinger, J., Gaebel, W., Morris Smith, L.,
Gorun, A., Prudent, V., Antonius, D., Trémeau, F., 2014.
Negative symptoms, past and present: a historical perspective
and moving to DSM-5. Eur. Neuropsychopharmacol. 24, 710–724.
Malhotra, D., Sebat, J., 2012. CNVs: Harbingers of a rare variant
revolution in psychiatric genetics. Cell 148, 1223–1441.
Manoliu, A., Riedl, V., Doll, A., Bäumi, J.G., Mühlau, M.,
Schwerthof̈fer, D., Scherr, M., Zimmer, C., For̈stl, H., Bäuml,
J., Wohlschläger, A.M., Koch, K., Sorg, C., 2013. Insular
dysfunction reﬂects altered between-network connectivity and
severity of negative symptoms in schizophrenia during psychotic
remission. Front. Hum. Neurosci. 7, 216.
Marder, S.R., Kirkpatrick, B., 2014. Deﬁning and measuring nega-
tive symptoms of schizophrenia in clinical trials. Eur. Neuropsy-
chopharmacol. 24, 737–743.
Markou, A., Salamone, J.D., Bussey, T.J., Mar, A.C., Brunner, D.,
Gilmour, G., Balsam, P., 2013. Measuring reinforcement learning
and motivation constructs in experimental animals: relevance to
the negative symptoms of schizophrenia. Neurosci. Biobehav.
Rev. 37, 2149–2165.
Marona-Lewicka, D., Nichols, C.D., Nichols, D.E., 2011. An animal
model of schizophrenia based on chronic LSD administration: old
idea, new results. Neuropharmacology 61, 503–512.
Marx, C.E., Bradford, D.W., Hamer, R.M., Naylor, J.C., Allen, T.B.,
Lieberman, J.A., Strauss, J.L., Kilts, J.D., 2011. Pregnenolone as
a novel therapeutic candidate in schizophrenia: emerging pre-
clinical and clinical evidence. Neuroscience 191, 78–90.
Masi, G., Mucci, M., Pari, C., 2006. Children with schizophrenia:
clinical picture and pharmacological treatment. CNS Drugs 20,
841–866.
Matsuoka, T., Sumiyoshi, T., Tanaka, K., Tsunoda, M., Uehara, T.,
Itoh, H., Kurachi, M., 2005. N-1900, an arginine-vasopressin
analogue, ameliorates social behavior deﬁcits and hyperlocomo-
tion in MK-801-treated rats: therapeutic implications for schizo-
phrenia. Brain Res. 1053, 131–136.
Matsuzawa, D., Obata, T., Shirayama, Y., Nonaka, H., Kanazawa, Y.,
Yoshitome, E., Takanashi, J., Matsuda, T., Shimizu, E., Ikehira, H.,
Iyo, M., Hashimoto, K., 2008. Negative correlation between brain
glutathione level and negative symptoms in schizophrenia: a 3T
1H-MRS study. PLoS One 3, e1944.
Mazza, M., Catalucci, A., Pino, M.C., Giusti, L., Nigri, A., Pollice, R.,
Roncone, R., Casacchia, M., Gallucci, M., 2013. Dysfunctional
neuronal networks associated with impaired social interactions in
early psychosis: an ICA analysis. Brain Imaging Behav. 7, 248–259.
McTighe, S.M., Neal, S.J., Lin, Q., Hughes, Z.A., Smith, D.G., 2013.
The BTBR mouse model of autism spectrum disorders has
learning and attentional impairments and alterations in acet-
ylcholine and kynurenic acid in prefrontal cortex. PLoS One 8,
e62189.
M.J. Millan et al.686Meffre, J., Chaumont-Dubel, S., Mannoury la Cour, C., Loiseau, F.,
Watson, D.J., Dekeyne, A., Séveno, M., Rivet, J.M., Gaven, F.,
Déléris, P., Hervé, D., Fone, K.C., Bockaert, J., Millan, M.J.,
Marin, P., 2012. 5-HT6 receptor recruitment of mTOR as a
mechanism for perturbed cognition in schizophrenia. EMBO
Mol. Med. 4, 1043–1056.
Mehta, U.M., Thirthalli, J., Subbakrishna, D.K., Gangadhar, B.N.,
Eack, S.M., Keshavan, M.S., 2013. Social and neuro-cognition as
distinct cognitive factors in schizophrenia: a systematic review.
Schizophr. Res. 148, 3–11.
Mehta, U.M., Thirthalli, J., Subbakrishna, D.K., Gangadhar, B.N.,
Messinger, J.W., Tremeau, F., Antonius, D., Mendelsohn, E.,
Prudent, V., Stanford, A.D., Malaspina, D., 2011. Avolition and
expressive deﬁcits capture negative symptom phenomenology:
implications for DSM-5 and schizophrenia research. Clin. Psy-
chol. Rev. 31, 161–168.
Meisenzahl, E.M., Schmitt, G., Gründer, G., Dresel, S., Frodl, T., la
Fougère, C., Scheuerecker, J., Schwarz, M., Boerner, R., Stauss,
J., Hahn, K., Mol̈ler, H.J., 2008. Striatal D2/D3 receptor
occupancy, clinical response and side effects with amisulpride:
an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry
41, 169–175.
Meltzer, H.Y., 2012. Serotonergic mechanisms as targets for existing
and novel antipsychotics. Handb. Exp. Pharmacol. 212, 87–124.
Messinger, J.W., Trémeau, F., Antonius, D., Mendelsohn, E., Pru-
dent, V., Stanford, A.D., Malaspina, D., 2011. Avolition and
expressive deﬁcits capture negative symptom phenomenology:
implications for DSM-5 and schizophrenia research. Clin. Psy-
chol. Rev. 31, 161–168.
Meyer, U., Feldon, J., 2010. Epidemiology-driven neurodevelop-
mental animal models of schizophrenia. Prog. Neurobiol. 90,
285–326.
Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M., 2011.
Oxytocin and vasopressin in the human brain: social neuropep-
tides for translational medicine. Nat. Rev. Neurosci. 12,
524–538.
Meyza, K.Z., Defensor, E.B., Jensen, A.L., Corley, M.J.,
Pearson, B.L., Pobbe, R.L., Bolivar, V.J., Blanchard, D.C.,
Blanchard, R.J., 2013. The BTBR T+ tf/J mouse model for
autism spectrum disorders-in search of biomarkers. Behav. Brain
Res. 251, 25–34.
Millan, M.J., 2005. NMDA receptors as a target for improved
antipsychotic agents: novel insights and clinical perspectives.
Psychopharmacology 179, 30–53.
Millan, M.J., 2006. Multi-target strategies for the improved treat-
ment of depressive states: conceptual foundations and neuronal
substrates, drug discovery and therapeutic application. Pharma-
col. Ther. 110, 135–370.
Millan, M.J., 2010. From the cell to the clinic: a comparative review
of the partial D2/D3 receptor agonist and α2-adrenoceptor
antagonist, piribedil, in the treatment of Parkinson’s disease.
Pharmacol. Ther. 128, 229–273.
Millan, M.J., 2013. An epigenetic framework for neurodevelopmen-
tal disorders: from pathogenesis to potential therapy. Neuro-
pharmacology 68, 2–82.
Millan, M.J., Agid, Y., Brüne, M., Bullmore, E.T., Carter, C.S.,
Clayton, N.S., Connor, R., Davis, S., Deakin, B., DeRubeis, R.J.,
Dubois, B., Geyer, M.A., Goodwin, G.M., Gorwood, P., Jay, T.M.,
Joëls, M., Mansuy, I.M., Meyer-Lindenberg, A., Murphy, D.,
Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington,
M., Young, L.J., 2012. Cognitive dysfunction in psychiatric
disorders: characteristics, causes and the quest for improved
therapy. Nat. Rev. 11, 141–168.
Millan, M.J., Bales, K.L., 2013. Towards improved animal models for
evaluating social cognition and its disruption in schizophrenia:
the CNTRICS initiative. Neurosci. Biobehav. Rev. 37, 2166–2180.
Millan, M.J., Brocco, M., 2008. Cognitive impairment in schizo-
phrenia: a review of developmental and genetic models, andpro-cognitive proﬁle of the optimised D34D2 antagonist,
S33138. Therapie 63, 187–229.
Millan, M.J., Brocco, M., Gobert, A., Joly, F., Bervoets, K., Rivet,
J.-M., Newman-Tancredi, A., Audinot, V., Maurel, S., 1999.
Contrasting mechanisms of action and sensitivity to antipsycho-
tics of phencyclidine versus amphetamine: importance of
nucleus accumbens 5-HT2A sites for PCP-induced locomotion in
the rat. Eur. J. Neurosci. 11, 4419–4432.
Millan, M.J., Brocco, M., Rivet, J.-M., Audinot, V., Newman-
Tancredi, A., Maioﬁss, L., Queriaux, S., Despaux, N., Peglion,
J.-L., Dekeyne, A., 2000. S18327 (1-[2-[4-(6-ﬂuoro-1, 2-benzi-
soxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a
novel, potential antipsychotic displaying marked antagonist
properties at alpha(1)- and alpha(2)-adrenergic receptors: II.
Functional proﬁle and a multiparametric comparison with
haloperidol, clozapine, and 11 other antipsychotic agents. J.
Pharmacol. Exp. Ther. 292, 54–66.
Millan, M.J., Di Cara, B., Dekeyne, A., Panayi, F., De Groote, L., Sicard,
D., Cistarelli, L., Billiras, R., Gobert, A., 2007. Selective blockade of
dopamine D3 vs D2 receptors enhances frontocortical cholinergic
transmission and social memory in rats: a parallel neurochemical
and behavioural analysis. J. Neurochem. 100, 1047–1061.
Mitchell, R.A., Herrmann, N., Lanctôt, K.L., 2011. The role of
dopamine in symptoms and treatment of apathy in Alzheimer's
disease. CNS Neurosci. Ther. 17, 411–427.
Miyamoto, S., Miyake, N., Jarskog, L.F., Fleischhacker, W.W.,
Lieberman, J.A., 2012. Pharmacological treatment of schizo-
phrenia: a critical review of the pharmacology and clinical
effects of current and future therapeutic agents. Mol. Psychiatry
17, 1206–1227.
Modabbernia, A., Rezael, F., Salehi, B., Jafarinia, M., Ashraﬁ,
M., Tabrizi, M., Hosseini, S.M., Tajdini, M., Ghaleiha, A.,
Akhondzadeh, S., 2013. Intranasal oxytocin as an adjunct to
risperidone in patients with schizophrenia: an 8-week,
randomized, double-blind, placebo-controlled study. CNS
Drugs 27, 57–65.
Mol̈ler, H.J., 2003. Amisulpride: limbic speciﬁcity and the mechan-
ism of antipsychotic atypicality. Prog. Neuropsychopharmacol.
Biol. Psychiatry 27, 1101–1111.
Montag, C., Brockmann, E.M., Bayerl, M., Rujescu, D., Muller, D.J.,
Gallinat, J., 2013. Oxytocin and oxytocin receptor gene poly-
morphisms and risk for schizophrenia: a case-control study.
World J. Psychiatry 14, 500–508.
Monte, A.S., de Souza, G.C., McIntyre, R.S., Soczynska, J.K., dos
Santos, J.V., Cordeiro, R.C., Ribeiro, B.M., de Lucena, D.F.,
Vasconcelos, S.M., de Sousa, F.C., Carvalho, A.F., Macêdo, D.S.,
2013. Prevention and reversal of ketamine-induced schizophrenia
related behavior by minocycline in mice: possible involvement of
antioxidant and nitrergic pathways. J. Psychopharmacol. 27,
1032–1043.
Morris, B.J., Cochran, S.M., Pratt, J.A., 2005. PCP: from pharma-
cology to modelling schizophrenia. Curr. Opin. Pharmacol. 5,
101–106.
Morris, R.W., Vercammen, A., Lenroot, R., Moore, L., Langton, J.
M., Short, B., Kulkami, J., Curtis, J., O’Donnell, M., Weickert,
C.S., Weickert, TW., 2012. Disambiguating ventral striatum
fMRI-related BOLD signal during expected reward prediction in
schizophrenia. Mol. Psychiatry 235, 280–289.
Morrison, A.P., Turkington, D., Pyle, M., Spencer, H., Brabban, A.,
Dunn, G., Christodoulides, T., Dudley, R., Chapman, N., Call-
cott, P., Grace, T., Lumley, V., Drage, L., Tully, S., Irving, K.,
Cummings, A., Byrne, R., Davies, L.M., Hutton, P., 2014.
Cognitive therapy for people with schizophrenia spectrum
disorders not taking antipsychotic drugs: a single-blind rando-
mized controlled trial. Lancet 42, 1049–1056.
Moser, P., 2014. Evaluating negative-symptom-like behavioural
changes in developmental models in schizophrenia. Eur. Neu-
ropsychopharmacol. 24, 774–787.
687Negative symptoms of schizophreniaMugnaini, M., Iavarone, L., Cavallini, P., Griffante, C., Oliosi, B.,
Savola, C., Beaver, J., Rabiner, E.A., Micheli, F., Heidbreder,
C., Andorn, A., Pich, E.M., Bani, M., 2013. Occupancy of brain
dopamine D3 receptors and drug craving: a translational
approach. Neuropsychopharmacology 38, 302–312.
Müller, N., Myint, A.M., Krause, D., Weidinger, E., Schwarz, M.J.,
2013. Anti-inﬂammatory treatment in schizophrenia. Prog.
Neuropsychopharmacol. Biol. Psychiatry 42, 146–153.
Murai, R., Noda, Y., Matsui, K., Kamei, H., Mouri, A., Matsuba, K.,
Nitta, A., Furukawa, H., Nabeshima, T., 2007. Hypofonctional
glutamatergic neurotransmission in the prefrontal cortex is
involved in the emotional deﬁcit induced by repeated treatment
with phencyclidine in mice: implications for abnormalities of
glutamate release and NMDA-CaMKII signaling. Behav. Brain Res.
180, 152–160.
Murphy, B.P., Chang, Y.C., Park, T.W., McGorry, P.D., 2006. Phar-
macological treatment of primary negative symptoms in schizo-
phrenia: a systematic review. Schizophr. Res. 88, 5–25.
Murray, E.A., Rudebeck, P.H., 2013. The drive to strive: goal
generation based on current needs. Front. Neurosci. Jun 27
(7), 112.
Naber, D., Lambert, M., 2009. The CATIE and CUtLASS studies in
schizophrenia: results and implications for clinicians. CNS Drugs
23, 649–659.
Nader, M.A., Nader, S.H., Czoty, P.W., Riddick, N.V., Gage, H.D.,
Gould, R.W., Blaylock, B.L., Kaplan, J.R., Garg, P.K., Davies, H.
M., Morton, D., Garg, S., Reboussin, B.A., 2012. Social dom-
inance in female monkeys: dopamine receptor functions and
cocaine reinforcement. Biol. Psychiatry 72, 414–421.
Nagai, T., Kitahara, Y., Ibi, D., Nabeshima, T., Sawa, A., Yamada, K.,
2011. Effects of antipsychotics on the behavioral deﬁcits in
human dominant-negative DISC1 transgenic mice with neonatal
poly l:C treatment. Behav. Brain Res. 225, 305–310.
Nagai, T., Kitahara, Y., Nabeshima, T., Yamada, K., 2012. D-serine
ameliorates neonatal Poly l:C treatment-induced emotional and
cognitive impairments in adult mice. J. Pharmacol. Sci. 120,
213–227.
Nakagami, E., Xie, B., Hoe, M., Brekke, J.S., 2008. Intrinsic
motivation, neurocognition and psychosocial functioning in
schizophrenia: testing mediator and moderator effects. Schi-
zophr. Res. 105, 95–104.
Nakajima, S., Gerretsen, P., Takeuchi, H., Caravaggio, F., Chow, T.,
Le Foll, B., Mulsant, B., Pollock, B., Graff-Guerrero, A., 2013.
The potential role of dopamine D3 receptor neurotransmission in
cognition. Eur. Neuropsychopharmacol. 23, 799–813.
Nakako, T., Murai, T., Ikejiri, M., Ishiyama, T., Taiji, M., Ikeda, K.,
2013. Effects of a dopamine D1 agonist on ketamine-induced
spatial working memory dysfunction in common marmosets.
Behav. Brain Res. 249, 109–115.
Nakamura, K., Takahashi, T., Nemoto, K., Furuichi, A., Nishiyama,
S., Nakamura, Y., Ikeda, E., Kido, M., Noguchi, K., Seto, H.,
Suzuki, M., 2013. Gray matter changes in subjects at high risk
for developing psychosis and ﬁrst-episode schizophrenia: a
voxel-based structural MRI study. Front. Psychiatry 4, 16.
Nakaya, M., Ohmori, K., 2008. A two-factor structure for the
schedule for the deﬁcit syndrome in schizophrenia. Psychiatry
Res. 158, 256–259.
Neill, J.C., Barnes, S., Cook, S., Grayson, B., Idris, N.F., McLean, S.L.,
Snigdha, S., Rajagopal, L., Harte, M.K., 2010. Animal models of
cognitive dysfunction and negative symptoms of schizophrenia:
focus on NMDA receptor antagonism. Pharmacol. Ther. 128, 419–432.
Neill, J.C., Harte, M.K., Haddad, P.M., Lydall, E.S., Dwyer, D.M.,
2014. Acute and chronic effects of NMDA receptor antagonists in
rodents, relevance to negative symptoms of schizophrenia: a
translational link to humans. Eur. Neuropsychopharmacol. 24,
822–835.
Nenadic, I., Maitra, R., Scherpiet, S., Gaser, C., Schultz, C.C.,
Schachtzabel, C., Smesny, S., Reichenbach, J.R., Treutlein, J.,Mühleisen, M.M., Deufel, T., Cichon, S., Rietschel, M., Noẗhen,
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